Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,27121335,tmax,"Sumatriptan achieved Cmax rapidly (median tmax : 0.8-1.5 hours for adolescents, 0.5-2.0 hours for adults); elimination was also rapid (geometric mean t½ : <2 hours for adolescents, 1.9-2.4 hours for adults).","Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121335/),h,0.8-1.5,2017,DB00788,Naproxen
,27121335,tmax,"Sumatriptan achieved Cmax rapidly (median tmax : 0.8-1.5 hours for adolescents, 0.5-2.0 hours for adults); elimination was also rapid (geometric mean t½ : <2 hours for adolescents, 1.9-2.4 hours for adults).","Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121335/),h,0.5-2.0,2018,DB00788,Naproxen
<,27121335,t½,"Sumatriptan achieved Cmax rapidly (median tmax : 0.8-1.5 hours for adolescents, 0.5-2.0 hours for adults); elimination was also rapid (geometric mean t½ : <2 hours for adolescents, 1.9-2.4 hours for adults).","Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121335/),h,2,2019,DB00788,Naproxen
,27121335,t½,"Sumatriptan achieved Cmax rapidly (median tmax : 0.8-1.5 hours for adolescents, 0.5-2.0 hours for adults); elimination was also rapid (geometric mean t½ : <2 hours for adolescents, 1.9-2.4 hours for adults).","Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121335/),h,1.9-2.4,2020,DB00788,Naproxen
,27121335,tmax,"Compared with sumatriptan, naproxen was absorbed and eliminated more slowly (median tmax : 1.0-4.0 hours for adolescents, 1.0-3.0 hours for adults; geometric mean t½ : 13.4-16.3 hours for adolescents, 14.3-16.6 hours for adults).","Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121335/),h,1.0-4.0,2021,DB00788,Naproxen
,27121335,tmax,"Compared with sumatriptan, naproxen was absorbed and eliminated more slowly (median tmax : 1.0-4.0 hours for adolescents, 1.0-3.0 hours for adults; geometric mean t½ : 13.4-16.3 hours for adolescents, 14.3-16.6 hours for adults).","Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121335/),h,1.0-3.0,2022,DB00788,Naproxen
,27121335,t½,"Compared with sumatriptan, naproxen was absorbed and eliminated more slowly (median tmax : 1.0-4.0 hours for adolescents, 1.0-3.0 hours for adults; geometric mean t½ : 13.4-16.3 hours for adolescents, 14.3-16.6 hours for adults).","Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121335/),h,13.4-16.3,2023,DB00788,Naproxen
,27121335,t½,"Compared with sumatriptan, naproxen was absorbed and eliminated more slowly (median tmax : 1.0-4.0 hours for adolescents, 1.0-3.0 hours for adults; geometric mean t½ : 13.4-16.3 hours for adolescents, 14.3-16.6 hours for adults).","Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121335/),h,14.3-16.6,2024,DB00788,Naproxen
,24954342,T1/2,"Diclofenac potassium had the lowest T1/2 and the highest mean Css, muscle/Css, plasma (1.9 hours and 0.85±0.53, respectively).",Concentration of non-steroidal anti-inflammatory drugs in the pelvic floor muscles: an experimental comparative rat model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24954342/),h,1.9,2086,DB00788,Naproxen
,24954342,"Css, muscle/Css","Diclofenac potassium had the lowest T1/2 and the highest mean Css, muscle/Css, plasma (1.9 hours and 0.85±0.53, respectively).",Concentration of non-steroidal anti-inflammatory drugs in the pelvic floor muscles: an experimental comparative rat model. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24954342/),,0.85,2087,DB00788,Naproxen
,29105796,area under the curve (AUC),Celecoxib showed the highest area under the curve (AUC) [146.50 ± 2.75 μg/mL*h] of all NSAID's.,Penetration and pharmacokinetics of non-steroidal anti-inflammatory drugs in rat prostate tissue. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29105796/),[μg] / [h·ml],146.50,2654,DB00788,Naproxen
,528094,tmax,In healthy volunteers the following values were obtained for various pharmacokinetic parameters: tmax = 2 hr; Cmax = 52.63 micrograms/ml; Ka = 1.893 hr-1; alpha = 0.393 hr-1; beta = 0.049 hr-1; K12 = 0.147 hr-1; K21 = 0.198 hr-1; K13 = 0.097 hr-1.,Pharmacokinetics of naproxen in healthy volunteers and in patients with diabetic microangiopathy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/528094/),h,2,3416,DB00788,Naproxen
,528094,Cmax,In healthy volunteers the following values were obtained for various pharmacokinetic parameters: tmax = 2 hr; Cmax = 52.63 micrograms/ml; Ka = 1.893 hr-1; alpha = 0.393 hr-1; beta = 0.049 hr-1; K12 = 0.147 hr-1; K21 = 0.198 hr-1; K13 = 0.097 hr-1.,Pharmacokinetics of naproxen in healthy volunteers and in patients with diabetic microangiopathy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/528094/),[μg] / [ml],52.63,3417,DB00788,Naproxen
,528094,Ka,In healthy volunteers the following values were obtained for various pharmacokinetic parameters: tmax = 2 hr; Cmax = 52.63 micrograms/ml; Ka = 1.893 hr-1; alpha = 0.393 hr-1; beta = 0.049 hr-1; K12 = 0.147 hr-1; K21 = 0.198 hr-1; K13 = 0.097 hr-1.,Pharmacokinetics of naproxen in healthy volunteers and in patients with diabetic microangiopathy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/528094/),1/[h],1.893,3418,DB00788,Naproxen
,528094,alpha,In healthy volunteers the following values were obtained for various pharmacokinetic parameters: tmax = 2 hr; Cmax = 52.63 micrograms/ml; Ka = 1.893 hr-1; alpha = 0.393 hr-1; beta = 0.049 hr-1; K12 = 0.147 hr-1; K21 = 0.198 hr-1; K13 = 0.097 hr-1.,Pharmacokinetics of naproxen in healthy volunteers and in patients with diabetic microangiopathy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/528094/),1/[h],0.393,3419,DB00788,Naproxen
,528094,beta,In healthy volunteers the following values were obtained for various pharmacokinetic parameters: tmax = 2 hr; Cmax = 52.63 micrograms/ml; Ka = 1.893 hr-1; alpha = 0.393 hr-1; beta = 0.049 hr-1; K12 = 0.147 hr-1; K21 = 0.198 hr-1; K13 = 0.097 hr-1.,Pharmacokinetics of naproxen in healthy volunteers and in patients with diabetic microangiopathy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/528094/),1/[h],0.049,3420,DB00788,Naproxen
,528094,K12,In healthy volunteers the following values were obtained for various pharmacokinetic parameters: tmax = 2 hr; Cmax = 52.63 micrograms/ml; Ka = 1.893 hr-1; alpha = 0.393 hr-1; beta = 0.049 hr-1; K12 = 0.147 hr-1; K21 = 0.198 hr-1; K13 = 0.097 hr-1.,Pharmacokinetics of naproxen in healthy volunteers and in patients with diabetic microangiopathy. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/528094/),1/[h],0.147,3421,DB00788,Naproxen
,528094,K21,In healthy volunteers the following values were obtained for various pharmacokinetic parameters: tmax = 2 hr; Cmax = 52.63 micrograms/ml; Ka = 1.893 hr-1; alpha = 0.393 hr-1; beta = 0.049 hr-1; K12 = 0.147 hr-1; K21 = 0.198 hr-1; K13 = 0.097 hr-1.,Pharmacokinetics of naproxen in healthy volunteers and in patients with diabetic microangiopathy. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/528094/),1/[h],0.198,3422,DB00788,Naproxen
,528094,K13,In healthy volunteers the following values were obtained for various pharmacokinetic parameters: tmax = 2 hr; Cmax = 52.63 micrograms/ml; Ka = 1.893 hr-1; alpha = 0.393 hr-1; beta = 0.049 hr-1; K12 = 0.147 hr-1; K21 = 0.198 hr-1; K13 = 0.097 hr-1.,Pharmacokinetics of naproxen in healthy volunteers and in patients with diabetic microangiopathy. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/528094/),1/[h],0.097,3423,DB00788,Naproxen
,32646357,flow rate,"Samples were eluted from the column at the flow rate of 1.4 mL/min using a mobile phase containing 0.2% triethylamine in water (pH 3.4 with formic acid): acetonitrile (45:55, v/v).",Simple and Fast Determination of Terbinafine in Human Urine by Dilute and Shoot HPLC-DAD Using a Core-Shell Column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32646357/),[ml] / [min],1.4,4144,DB00788,Naproxen
,32646357,limit of detection,The limit of detection was 12.60 ng/mL.,Simple and Fast Determination of Terbinafine in Human Urine by Dilute and Shoot HPLC-DAD Using a Core-Shell Column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32646357/),[ng] / [ml],12.60,4145,DB00788,Naproxen
,10707114,elimination half life,There was a significant (p < 0.05) increase in mean elimination half life (2.39 +/- 0.42 to 3.59 +/- 0.35 h) following ibuprofen and diazepam administration compared to ibuprofen alone administered at 22.00 hours.,Time dependent influence of diazepam on the pharmacokinetics of ibuprofen in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10707114/),h,2.39,4552,DB00788,Naproxen
,10707114,elimination half life,There was a significant (p < 0.05) increase in mean elimination half life (2.39 +/- 0.42 to 3.59 +/- 0.35 h) following ibuprofen and diazepam administration compared to ibuprofen alone administered at 22.00 hours.,Time dependent influence of diazepam on the pharmacokinetics of ibuprofen in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10707114/),h,3.59,4553,DB00788,Naproxen
,10707114,clearance,The mean clearance of ibuprofen was therefore lowered from 62.7 +/- 8.9 to 41.7 +/- 2.6 ml/h/kg under the influence of diazepam during the night.,Time dependent influence of diazepam on the pharmacokinetics of ibuprofen in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10707114/),[ml] / [h·kg],62.7,4554,DB00788,Naproxen
,10707114,clearance,The mean clearance of ibuprofen was therefore lowered from 62.7 +/- 8.9 to 41.7 +/- 2.6 ml/h/kg under the influence of diazepam during the night.,Time dependent influence of diazepam on the pharmacokinetics of ibuprofen in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10707114/),[ml] / [h·kg],41.7,4555,DB00788,Naproxen
,8373716,AUC,"The mean AUC value for the glucuronidated metabolite, GZDV, was reduced from 26.6 +/- 11.7 mumol l-1 h in the presence of placebo to 20.9 +/- 8.3 mumol l-1 h (95% C.I. of the difference 1.39-9.98; P < 0.05) following treatment with naproxen 250 mg twice daily for 3 days.",The effects of indomethacin and naproxen on zidovudine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373716/),[h·μM] / [l],26.6,5535,DB00788,Naproxen
,8373716,AUC,"The mean AUC value for the glucuronidated metabolite, GZDV, was reduced from 26.6 +/- 11.7 mumol l-1 h in the presence of placebo to 20.9 +/- 8.3 mumol l-1 h (95% C.I. of the difference 1.39-9.98; P < 0.05) following treatment with naproxen 250 mg twice daily for 3 days.",The effects of indomethacin and naproxen on zidovudine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373716/),[h·μM] / [l],20.9,5536,DB00788,Naproxen
,8512758,elimination half-life,2. The mean elimination half-life of naproxen was 24.7 +/- 6.4 h (range 7 to 36 h).,"The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512758/),h,24.7,6398,DB00788,Naproxen
,8512758,plasma binding,"5. The extents of plasma binding of the unconjugated compounds were 98% (naproxen) and 100% (O-desmethylnaproxen), while naproxen acyl glucuronide binding was 92%; that of its isomer isoglucuronide 66%.","The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512758/),%,98,6399,DB00788,Naproxen
,8512758,plasma binding,"5. The extents of plasma binding of the unconjugated compounds were 98% (naproxen) and 100% (O-desmethylnaproxen), while naproxen acyl glucuronide binding was 92%; that of its isomer isoglucuronide 66%.","The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512758/),%,100,6400,DB00788,Naproxen
,8512758,plasma binding,"5. The extents of plasma binding of the unconjugated compounds were 98% (naproxen) and 100% (O-desmethylnaproxen), while naproxen acyl glucuronide binding was 92%; that of its isomer isoglucuronide 66%.","The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512758/),%,92,6401,DB00788,Naproxen
,8512758,plasma binding,"5. The extents of plasma binding of the unconjugated compounds were 98% (naproxen) and 100% (O-desmethylnaproxen), while naproxen acyl glucuronide binding was 92%; that of its isomer isoglucuronide 66%.","The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512758/),%,66,6402,DB00788,Naproxen
,8512758,binding,"5. The extents of plasma binding of the unconjugated compounds were 98% (naproxen) and 100% (O-desmethylnaproxen), while naproxen acyl glucuronide binding was 92%; that of its isomer isoglucuronide 66%.","The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512758/),%,92,6403,DB00788,Naproxen
,8512758,binding,"5. The extents of plasma binding of the unconjugated compounds were 98% (naproxen) and 100% (O-desmethylnaproxen), while naproxen acyl glucuronide binding was 92%; that of its isomer isoglucuronide 66%.","The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512758/),%,66,6404,DB00788,Naproxen
,8512758,t1/2,6. Cimetidine (400 mg twice daily) decreased the t1/2 of naproxen by 39-60% (mean 47.3 +/- 11.5%; P = 0.0014) from 24.7 +/- 6.4 h to 13.2 +/- 1.0 h.,"The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512758/),h,24.7,6405,DB00788,Naproxen
,8512758,t1/2,6. Cimetidine (400 mg twice daily) decreased the t1/2 of naproxen by 39-60% (mean 47.3 +/- 11.5%; P = 0.0014) from 24.7 +/- 6.4 h to 13.2 +/- 1.0 h.,"The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512758/),h,13.2,6406,DB00788,Naproxen
,23794721,extraction recovery,The extraction recovery values of naproxen from human plasma were between 91.0 and 98.9%.,HPLC method for naproxen determination in human plasma and its application to a pharmacokinetic study in Turkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23794721/),%,91.0 and 98.9,7440,DB00788,Naproxen
,23794721,limits of detection,"The limits of detection and quantification of naproxen were 0.03 and 0.10 µg/mL, respectively.",HPLC method for naproxen determination in human plasma and its application to a pharmacokinetic study in Turkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23794721/),[μg] / [ml],0.03,7441,DB00788,Naproxen
,23794721,limits of detection,"The limits of detection and quantification of naproxen were 0.03 and 0.10 µg/mL, respectively.",HPLC method for naproxen determination in human plasma and its application to a pharmacokinetic study in Turkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23794721/),[μg] / [ml],0.10,7442,DB00788,Naproxen
,27774912,globule,"The optimized formulation has globule size- 187.6 nm, zeta potential- -9.81 mv, viscosity- 1.772 cps and infinite dilution ability.",Development of Self Emulsifying Formulations of Poorly Soluble Naproxen for Enhanced Drug Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27774912/),nm,187.6,10869,DB00788,Naproxen
,27774912,zeta potential,"The optimized formulation has globule size- 187.6 nm, zeta potential- -9.81 mv, viscosity- 1.772 cps and infinite dilution ability.",Development of Self Emulsifying Formulations of Poorly Soluble Naproxen for Enhanced Drug Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27774912/),mv,9.81,10870,DB00788,Naproxen
,27774912,viscosity,"The optimized formulation has globule size- 187.6 nm, zeta potential- -9.81 mv, viscosity- 1.772 cps and infinite dilution ability.",Development of Self Emulsifying Formulations of Poorly Soluble Naproxen for Enhanced Drug Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27774912/),cps,1.772,10871,DB00788,Naproxen
,27774912,drug release,In vitro drug release was 98.21% and was found to be significantly different from the marketed product and plain drug.,Development of Self Emulsifying Formulations of Poorly Soluble Naproxen for Enhanced Drug Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27774912/),%,98.21,10872,DB00788,Naproxen
,27774912,"Cmax, AUC0t","The Cmax, AUC0t of naproxen was boosted with SEDDS to 133.63 g/ml and 698.29 hr.",Development of Self Emulsifying Formulations of Poorly Soluble Naproxen for Enhanced Drug Delivery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27774912/),[g] / [ml],133.63,10873,DB00788,Naproxen
,27774912,"Cmax, AUC0t","The Cmax, AUC0t of naproxen was boosted with SEDDS to 133.63 g/ml and 698.29 hr.",Development of Self Emulsifying Formulations of Poorly Soluble Naproxen for Enhanced Drug Delivery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27774912/),h,698.29,10874,DB00788,Naproxen
,16569489,flow rate,The flow rate was 3.5 ml/min and the effluent was monitored by fluorescence with excitation at 230 nm and emission at 410 nm.,Determination of furosemide in plasma and urine using monolithic silica rod liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16569489/),[ml] / [min],3.5,12425,DB00788,Naproxen
,16569489,retention times,"The retention times for the internal standard (naproxen) and for furosemide were 2.1 and 3.7 min, respectively, and total run time was 8 min.",Determination of furosemide in plasma and urine using monolithic silica rod liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16569489/),min,2.1,12426,DB00788,Naproxen
,16569489,retention times,"The retention times for the internal standard (naproxen) and for furosemide were 2.1 and 3.7 min, respectively, and total run time was 8 min.",Determination of furosemide in plasma and urine using monolithic silica rod liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16569489/),min,3.7,12427,DB00788,Naproxen
,16569489,total run time,"The retention times for the internal standard (naproxen) and for furosemide were 2.1 and 3.7 min, respectively, and total run time was 8 min.",Determination of furosemide in plasma and urine using monolithic silica rod liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16569489/),min,8,12428,DB00788,Naproxen
,7263110,Cmax,"The average value of Cmax is 18.55 +/- 7.05 micrograms/ml, far lower than that obtained in healthy volunteers.",Pharmacokinetics of naproxen in patients with hypoproteinemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7263110/),[μg] / [ml],18.55,12618,DB00788,Naproxen
,7263110,bioavailability,The bioavailability compared with healthy volunteers receiving the same dose was 45.55%.,Pharmacokinetics of naproxen in patients with hypoproteinemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7263110/),%,45.55,12619,DB00788,Naproxen
,9754983,AUC ratio,"The AUC ratio, (NSAID +omeprazole):NSAID alone, was 1.11, 0.99, and 0.99 for diclofenac, naproxen, and piroxicam, respectively.",Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754983/),,1.11,15134,DB00788,Naproxen
,9754983,AUC ratio,"The AUC ratio, (NSAID +omeprazole):NSAID alone, was 1.11, 0.99, and 0.99 for diclofenac, naproxen, and piroxicam, respectively.",Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754983/),,0.99,15135,DB00788,Naproxen
,9330782,SF-serum concentration ratios,Similar SF-serum concentration ratios of naproxen were found between i.v. (0.61 +/- 0.16) and topical (0.55 +/- 0.14) routes of administration.,Pharmacokinetic and local tissue disposition studies of naproxen-following topical and systemic administration in dogs and rats. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330782/),,0.61,19867,DB00788,Naproxen
,9330782,SF-serum concentration ratios,Similar SF-serum concentration ratios of naproxen were found between i.v. (0.61 +/- 0.16) and topical (0.55 +/- 0.14) routes of administration.,Pharmacokinetic and local tissue disposition studies of naproxen-following topical and systemic administration in dogs and rats. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330782/),,0.55,19868,DB00788,Naproxen
,9330782,half-life,"Following the i.v. dose, the half-life of naproxen in SF (approximately 60 h) was significantly longer than that in serum (approximately 40 h).",Pharmacokinetic and local tissue disposition studies of naproxen-following topical and systemic administration in dogs and rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330782/),h,60,19869,DB00788,Naproxen
,9330782,half-life,"Following the i.v. dose, the half-life of naproxen in SF (approximately 60 h) was significantly longer than that in serum (approximately 40 h).",Pharmacokinetic and local tissue disposition studies of naproxen-following topical and systemic administration in dogs and rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330782/),h,40,19870,DB00788,Naproxen
,9330782,bioavailability,The bioavailability of naproxen in the topical gel was approximately 2% of the applied dose in dogs.,Pharmacokinetic and local tissue disposition studies of naproxen-following topical and systemic administration in dogs and rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330782/),%,2,19871,DB00788,Naproxen
,7151646,elimination rate constant,"The mean elimination rate constant was greater in the febrile children than the postoperative patients, 0.064 h-1 vs.",Pharmacokinetics and metabolism of naproxen in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7151646/),1/[h],0.064,24364,DB00788,Naproxen
,15664346,detection,"The detection and quantification limits for the three flavonoids were similar being 3 and 5 ng/ml, respectively.",Determination of flavonoids from Orthosiphon stamineus in plasma using a simple HPLC method with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664346/),[ng] / [ml],3,25971,DB00788,Naproxen
,15664346,quantification limits,"The detection and quantification limits for the three flavonoids were similar being 3 and 5 ng/ml, respectively.",Determination of flavonoids from Orthosiphon stamineus in plasma using a simple HPLC method with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664346/),[ng] / [ml],5,25972,DB00788,Naproxen
,15664346,recovery,"In addition, the mean recovery values of the extraction procedure for all the flavonoids were between 92 and 114%.",Determination of flavonoids from Orthosiphon stamineus in plasma using a simple HPLC method with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664346/),%,92 and 114,25973,DB00788,Naproxen
,15664346,absolute oral bioavailability,"The present method was applied to analyse plasma samples obtained from a pilot study using rats in which the mean absolute oral bioavailability values for sinensitin, eupatorin and 3'-hydroxy-5,6,7,4'-tetramethoxyflavone was 9.4, 1.0 and 1.5%, respectively.",Determination of flavonoids from Orthosiphon stamineus in plasma using a simple HPLC method with ultraviolet detection. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664346/),%,9.4,25974,DB00788,Naproxen
,15664346,absolute oral bioavailability,"The present method was applied to analyse plasma samples obtained from a pilot study using rats in which the mean absolute oral bioavailability values for sinensitin, eupatorin and 3'-hydroxy-5,6,7,4'-tetramethoxyflavone was 9.4, 1.0 and 1.5%, respectively.",Determination of flavonoids from Orthosiphon stamineus in plasma using a simple HPLC method with ultraviolet detection. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664346/),%,1.0,25975,DB00788,Naproxen
,15664346,absolute oral bioavailability,"The present method was applied to analyse plasma samples obtained from a pilot study using rats in which the mean absolute oral bioavailability values for sinensitin, eupatorin and 3'-hydroxy-5,6,7,4'-tetramethoxyflavone was 9.4, 1.0 and 1.5%, respectively.",Determination of flavonoids from Orthosiphon stamineus in plasma using a simple HPLC method with ultraviolet detection. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664346/),%,1.5,25976,DB00788,Naproxen
,6970498,detection limit,"As an example, the practical detection limit for naproxen in plasma was about 0.2 microgram ml-1.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[μg] / [ml],0.2,31759,DB00788,Naproxen
,6970498,Vc,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[1] / [kg],0.038,31760,DB00788,Naproxen
,6970498,Vdss,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[1] / [kg],0.138,31761,DB00788,Naproxen
,6970498,t 1/2 (beta,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,21.3,31762,DB00788,Naproxen
,6970498,t 1/2 (alpha),"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,0.99,31763,DB00788,Naproxen
,6970498,t 1/2 (ka),"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,0.67,31764,DB00788,Naproxen
,14570719,total number of,"On naproxen, the mean total number of gastroduodenal erosions was 11.5 (and one subject developed an acute ulcer) versus 4.1 on AZD3582 (p<0.0001).","Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570719/),,11.5,37234,DB00788,Naproxen
,14570719,total number of,"On naproxen, the mean total number of gastroduodenal erosions was 11.5 (and one subject developed an acute ulcer) versus 4.1 on AZD3582 (p<0.0001).","Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570719/),,4.1,37235,DB00788,Naproxen
,14570719,steady state bioavailability,The steady state bioavailability of naproxen metabolised from AZD3582 was 95% (95% confidence interval 87-101%) of that after naproxen administration.,"Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570719/),%,95,37236,DB00788,Naproxen
,7325471,elimination half-life,"After IV injection of a 5 mg/kg dose, plasma concentrations decreased biexponentially, with an average elimination half-life of 74 hours.",Pharmacokinetics of naproxen in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7325471/),h,74,40436,DB00788,Naproxen
,7325471,apparent volume of distribution,The drug was highly protein-bound (greater than 99%) and had a correspondingly low apparent volume of distribution (0.13 L/kg).,Pharmacokinetics of naproxen in the dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7325471/),[l] / [kg],0.13,40437,DB00788,Naproxen
,7325471,bioavailability,"After naproxen was given orally, absorption was rapid, and the bioavailability ranged between 68% and 100%.",Pharmacokinetics of naproxen in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7325471/),%,68,40438,DB00788,Naproxen
,7325471,bioavailability,"After naproxen was given orally, absorption was rapid, and the bioavailability ranged between 68% and 100%.",Pharmacokinetics of naproxen in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7325471/),%,100,40439,DB00788,Naproxen
,2273487,elimination half-life,The mean MTX elimination half-life was prolonged when NSAID were coadministered (1.7 +/- 0.5 vs 1.2 +/- 0.1 h; p = 0.03).,Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),h,1.7,45863,DB00788,Naproxen
,2273487,elimination half-life,The mean MTX elimination half-life was prolonged when NSAID were coadministered (1.7 +/- 0.5 vs 1.2 +/- 0.1 h; p = 0.03).,Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),h,1.2,45864,DB00788,Naproxen
,2273487,apparent MTX clearance (CI),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),[l] / [h],10.6,45865,DB00788,Naproxen
,2273487,apparent MTX clearance (CI),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),[l] / [h],13.1,45866,DB00788,Naproxen
,2273487,area under the serum MTX concentration-time curve (Auc),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),[μM] / [h·l],2.1,45867,DB00788,Naproxen
,2273487,area under the serum MTX concentration-time curve (Auc),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),[μM] / [h·l],1.5,45868,DB00788,Naproxen
,2273487,apparent volume of distribution (Vd),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),l,23.0,45869,DB00788,Naproxen
,2273487,apparent volume of distribution (Vd),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),l,21.9,45870,DB00788,Naproxen
,17009840,C(max),"The parameters obtained (mean +/- S.E.M.) were: C(max) 43.93 +/- 1.83 and 44.91 +/- 2.15 microg/ml, t(max) 2.38 +/- 0.21 and 1.83 < or = 0.19 h, AUC(72 h) 721.73 +/- 18.47 and 722.55 +/- 19.07 microg x h/ml for reference and test formulations, respectively.",Comparative bioavailability of two oral suspensions of naproxen sodium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17009840/),[μg] / [ml],43.93,46834,DB00788,Naproxen
,17009840,C(max),"The parameters obtained (mean +/- S.E.M.) were: C(max) 43.93 +/- 1.83 and 44.91 +/- 2.15 microg/ml, t(max) 2.38 +/- 0.21 and 1.83 < or = 0.19 h, AUC(72 h) 721.73 +/- 18.47 and 722.55 +/- 19.07 microg x h/ml for reference and test formulations, respectively.",Comparative bioavailability of two oral suspensions of naproxen sodium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17009840/),[μg] / [ml],44.91,46835,DB00788,Naproxen
,17009840,t(max),"The parameters obtained (mean +/- S.E.M.) were: C(max) 43.93 +/- 1.83 and 44.91 +/- 2.15 microg/ml, t(max) 2.38 +/- 0.21 and 1.83 < or = 0.19 h, AUC(72 h) 721.73 +/- 18.47 and 722.55 +/- 19.07 microg x h/ml for reference and test formulations, respectively.",Comparative bioavailability of two oral suspensions of naproxen sodium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17009840/),h,2.38,46836,DB00788,Naproxen
,17009840,t(max),"The parameters obtained (mean +/- S.E.M.) were: C(max) 43.93 +/- 1.83 and 44.91 +/- 2.15 microg/ml, t(max) 2.38 +/- 0.21 and 1.83 < or = 0.19 h, AUC(72 h) 721.73 +/- 18.47 and 722.55 +/- 19.07 microg x h/ml for reference and test formulations, respectively.",Comparative bioavailability of two oral suspensions of naproxen sodium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17009840/),h,1.83,46837,DB00788,Naproxen
,17009840,AUC(72 h),"The parameters obtained (mean +/- S.E.M.) were: C(max) 43.93 +/- 1.83 and 44.91 +/- 2.15 microg/ml, t(max) 2.38 +/- 0.21 and 1.83 < or = 0.19 h, AUC(72 h) 721.73 +/- 18.47 and 722.55 +/- 19.07 microg x h/ml for reference and test formulations, respectively.",Comparative bioavailability of two oral suspensions of naproxen sodium. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17009840/),[h·μg] / [ml],721.73,46838,DB00788,Naproxen
,17009840,AUC(72 h),"The parameters obtained (mean +/- S.E.M.) were: C(max) 43.93 +/- 1.83 and 44.91 +/- 2.15 microg/ml, t(max) 2.38 +/- 0.21 and 1.83 < or = 0.19 h, AUC(72 h) 721.73 +/- 18.47 and 722.55 +/- 19.07 microg x h/ml for reference and test formulations, respectively.",Comparative bioavailability of two oral suspensions of naproxen sodium. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17009840/),[h·μg] / [ml],722.55,46839,DB00788,Naproxen
,22067196,oral clearance (CL/F),The estimated oral clearance (CL/F) was 0.62 L/h when linearly scaled by weight to 70 kg.,Plasma and cerebrospinal fluid pharmacokinetics of naproxen in children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22067196/),[l] / [h],0.62,53901,DB00788,Naproxen
,22067196,apparent volume of distribution at steady state (Vss/F),The apparent volume of distribution at steady state (Vss/F) was 12.5 L /70 kg.,Plasma and cerebrospinal fluid pharmacokinetics of naproxen in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22067196/),[l] / [70·kg],12.5,53902,DB00788,Naproxen
,2480587,absorption fractions,"As calculated relative to an equivalent oral dose of parent naproxen, the absorption fractions of all the derivatives were close to 100%.",Macromolecular prodrugs. Colon-targeted delivery--bioavailability of naproxen from orally administered dextran-naproxen ester prodrugs varying in molecular size in the pig. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2480587/),%,100,56156,DB00788,Naproxen
,2480587,lag time,The naproxen plasma profiles for all the administered prodrugs exhibited a characteristic lag time of naproxen appearance in the blood (2-3 hr).,Macromolecular prodrugs. Colon-targeted delivery--bioavailability of naproxen from orally administered dextran-naproxen ester prodrugs varying in molecular size in the pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2480587/),h,2-3,56157,DB00788,Naproxen
,22477200,AUC,The results showed moderate oral bioavailability of prodrugs (AUC = 53-94 h · μg/mL) in rats compared with parent Nap (AUC = 155 h · μg/mL) at equimolar doses.,Pharmacokinetic and ulcerogenic studies of naproxen prodrugs designed for specific brain delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22477200/),[h·μg] / [ml],53-94,60385,DB00788,Naproxen
,22477200,AUC,The results showed moderate oral bioavailability of prodrugs (AUC = 53-94 h · μg/mL) in rats compared with parent Nap (AUC = 155 h · μg/mL) at equimolar doses.,Pharmacokinetic and ulcerogenic studies of naproxen prodrugs designed for specific brain delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22477200/),[h·μg] / [ml],155,60386,DB00788,Naproxen
,8415407,pKa's,Potentiometrically determined pKa's for prodrugs were in the range of 6.89 to 8.62 at 25 degrees C.,Synthesis and evaluation of morpholinoalkyl ester prodrugs of indomethacin and naproxen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8415407/),,6.89 to 8.62,60436,DB00788,Naproxen
,8415407,half-lives,"The esters were generally found to be hydrolyzed rapidly in rat plasma at 37 degrees C, the half-lives being in the range of 1.2-31.0 min.",Synthesis and evaluation of morpholinoalkyl ester prodrugs of indomethacin and naproxen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8415407/),min,1.2-31.0,60437,DB00788,Naproxen
,26902772,mean residence time,"In vivo pharmacokinetics, EMZ-MRPs had significantly larger AUC0-t (p < 0.01), 1.67 times more than that of EMZ-IRPs, and prolonged mean residence time (7.55 ± 0.12 h) than that of IRPs (1.46 ± 0.39 h).",Novel naproxen/esomeprazole magnesium compound pellets based on acid-independent mechanism: in vitro and in vivo evaluation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902772/),h,7.55,65732,DB00788,Naproxen
,26902772,mean residence time,"In vivo pharmacokinetics, EMZ-MRPs had significantly larger AUC0-t (p < 0.01), 1.67 times more than that of EMZ-IRPs, and prolonged mean residence time (7.55 ± 0.12 h) than that of IRPs (1.46 ± 0.39 h).",Novel naproxen/esomeprazole magnesium compound pellets based on acid-independent mechanism: in vitro and in vivo evaluation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902772/),h,1.46,65733,DB00788,Naproxen
up to,30828406,terminal elimination half-life,"This was a randomized, single-dose, 2-way crossover, open-label, comparative bioavailability, pharmacokinetic study in 18 healthy male and female volunteers with a 5- to 8-day washout permitted between doses (based on the anticipated minimum washout period for naproxen determined from the known terminal elimination half-life of up to 17 hours).",Bioequivalence of 2 Naproxen Sodium Tablet Formulations in Healthy Male and Female Volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30828406/),h,17,65974,DB00788,Naproxen
,30828406,Cmax,"Following a single-dose administration of naproxen sodium tablets (2 × 220 mg), the Cmax and AUC0-t (geometric least squares mean) for the test product was 65.88 µg/mL and 893.37 h * µg/mL, respectively; and for the reference product was 64.59 µg/mL and 890.60 h * µg/mL.",Bioequivalence of 2 Naproxen Sodium Tablet Formulations in Healthy Male and Female Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30828406/),[μg] / [ml],65.88,65975,DB00788,Naproxen
,30828406,Cmax,"Following a single-dose administration of naproxen sodium tablets (2 × 220 mg), the Cmax and AUC0-t (geometric least squares mean) for the test product was 65.88 µg/mL and 893.37 h * µg/mL, respectively; and for the reference product was 64.59 µg/mL and 890.60 h * µg/mL.",Bioequivalence of 2 Naproxen Sodium Tablet Formulations in Healthy Male and Female Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30828406/),[μg] / [ml],64.59,65976,DB00788,Naproxen
,30828406,AUC0-t,"Following a single-dose administration of naproxen sodium tablets (2 × 220 mg), the Cmax and AUC0-t (geometric least squares mean) for the test product was 65.88 µg/mL and 893.37 h * µg/mL, respectively; and for the reference product was 64.59 µg/mL and 890.60 h * µg/mL.",Bioequivalence of 2 Naproxen Sodium Tablet Formulations in Healthy Male and Female Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30828406/),[h·μg] / [ml],893.37,65977,DB00788,Naproxen
,30828406,AUC0-t,"Following a single-dose administration of naproxen sodium tablets (2 × 220 mg), the Cmax and AUC0-t (geometric least squares mean) for the test product was 65.88 µg/mL and 893.37 h * µg/mL, respectively; and for the reference product was 64.59 µg/mL and 890.60 h * µg/mL.",Bioequivalence of 2 Naproxen Sodium Tablet Formulations in Healthy Male and Female Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30828406/),[h·μg] / [ml],890.60,65978,DB00788,Naproxen
,16354398,plasma protein binding degree,"AZD3582 has a predicted plasma protein binding degree of approximately 0.1%, a half-life (t1/2) of 3 to 10 h and does not accumulate after repeated once- and twice-daily dosing.",Clinical pharmacokinetics of the cyclooxygenase inhibiting nitric oxide donator (CINOD) AZD3582. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16354398/),%,0.1,68560,DB00788,Naproxen
,16354398,half-life (t1/2),"AZD3582 has a predicted plasma protein binding degree of approximately 0.1%, a half-life (t1/2) of 3 to 10 h and does not accumulate after repeated once- and twice-daily dosing.",Clinical pharmacokinetics of the cyclooxygenase inhibiting nitric oxide donator (CINOD) AZD3582. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16354398/),h,3 to 10,68561,DB00788,Naproxen
,16354398,F,The uptake of naproxen is slightly slower and lower (> or = 94% relative GI uptake and 80-85% relative F) after AZD3582 administration compared with naproxen dosing.,Clinical pharmacokinetics of the cyclooxygenase inhibiting nitric oxide donator (CINOD) AZD3582. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16354398/),%,94,68562,DB00788,Naproxen
,16354398,F,The uptake of naproxen is slightly slower and lower (> or = 94% relative GI uptake and 80-85% relative F) after AZD3582 administration compared with naproxen dosing.,Clinical pharmacokinetics of the cyclooxygenase inhibiting nitric oxide donator (CINOD) AZD3582. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16354398/),%,80-85,68563,DB00788,Naproxen
,3643850,pre-dose,"The mean pre-dose concentration on days 19, 20 and 21 was significantly higher in the elderly patients than in the controls (60.1 vs. 43.3 micrograms X ml-1).",Pharmacokinetics of naproxen in elderly patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3643850/),,60.1,69077,DB00788,Naproxen
,3643850,pre-dose,"The mean pre-dose concentration on days 19, 20 and 21 was significantly higher in the elderly patients than in the controls (60.1 vs. 43.3 micrograms X ml-1).",Pharmacokinetics of naproxen in elderly patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3643850/),,43.3,69078,DB00788,Naproxen
,3643850,concentration,"The mean pre-dose concentration on days 19, 20 and 21 was significantly higher in the elderly patients than in the controls (60.1 vs. 43.3 micrograms X ml-1).",Pharmacokinetics of naproxen in elderly patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3643850/),,60.1,69079,DB00788,Naproxen
,3643850,concentration,"The mean pre-dose concentration on days 19, 20 and 21 was significantly higher in the elderly patients than in the controls (60.1 vs. 43.3 micrograms X ml-1).",Pharmacokinetics of naproxen in elderly patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3643850/),,43.3,69080,DB00788,Naproxen
,3643850,AUC (0-24),The AUC (0-24) was significantly higher in the elderly subjects only when normalized for body weight (9.1 vs. 5.4 micrograms X ml-1 X h kg-1 p less than or equal to 0.02).,Pharmacokinetics of naproxen in elderly patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3643850/),[h·μg] / [kg·ml],9.1,69081,DB00788,Naproxen
,3643850,AUC (0-24),The AUC (0-24) was significantly higher in the elderly subjects only when normalized for body weight (9.1 vs. 5.4 micrograms X ml-1 X h kg-1 p less than or equal to 0.02).,Pharmacokinetics of naproxen in elderly patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3643850/),[h·μg] / [kg·ml],5.4,69082,DB00788,Naproxen
,3643850,apparent clearance,The apparent clearance of naproxen was reduced in the elderly compared to the control patients (315 vs. 628 ml X h-1).,Pharmacokinetics of naproxen in elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3643850/),[ml] / [h],315,69083,DB00788,Naproxen
,3643850,apparent clearance,The apparent clearance of naproxen was reduced in the elderly compared to the control patients (315 vs. 628 ml X h-1).,Pharmacokinetics of naproxen in elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3643850/),[ml] / [h],628,69084,DB00788,Naproxen
,3643850,percentage protein binding,The percentage protein binding of naproxen was the same in both groups (99.8%) but the free concentration of naproxen was significantly higher in the elderly patients than in the control patients (141 vs. 89.8 ng X ml-1).,Pharmacokinetics of naproxen in elderly patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3643850/),%,99.8,69085,DB00788,Naproxen
,3643850,percentage protein binding,The percentage protein binding of naproxen was the same in both groups (99.8%) but the free concentration of naproxen was significantly higher in the elderly patients than in the control patients (141 vs. 89.8 ng X ml-1).,Pharmacokinetics of naproxen in elderly patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3643850/),[ng] / [ml],141,69086,DB00788,Naproxen
,3643850,free concentration,The percentage protein binding of naproxen was the same in both groups (99.8%) but the free concentration of naproxen was significantly higher in the elderly patients than in the control patients (141 vs. 89.8 ng X ml-1).,Pharmacokinetics of naproxen in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3643850/),[ng] / [ml],141,69087,DB00788,Naproxen
,3643850,free concentration,The percentage protein binding of naproxen was the same in both groups (99.8%) but the free concentration of naproxen was significantly higher in the elderly patients than in the control patients (141 vs. 89.8 ng X ml-1).,Pharmacokinetics of naproxen in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3643850/),[ng] / [ml],89.8,69088,DB00788,Naproxen
,15030883,total ch,Separation was achieved within a total chromatographic run time of 18 min at 1.0 ml/min flow rate using a Hv PURITY C18 column.,Development of a high pressure liquid chromatography method for the determination of mycophenolic acid and its glucuronide metabolite in small volumes of plasma from paediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15030883/),min,18,69843,DB00788,Naproxen
,15030883,flow rate,Separation was achieved within a total chromatographic run time of 18 min at 1.0 ml/min flow rate using a Hv PURITY C18 column.,Development of a high pressure liquid chromatography method for the determination of mycophenolic acid and its glucuronide metabolite in small volumes of plasma from paediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15030883/),[ml] / [min],1.0,69844,DB00788,Naproxen
,15030883,limit of detection,The limit of detection was 0.1 microg/ml for both MPAG and MPA.,Development of a high pressure liquid chromatography method for the determination of mycophenolic acid and its glucuronide metabolite in small volumes of plasma from paediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15030883/),[μg] / [ml],0.1,69845,DB00788,Naproxen
,15030883,extraction recovery,"The average extraction recovery from plasma was 93.06%, for MPA and 92.41% for MPAG.",Development of a high pressure liquid chromatography method for the determination of mycophenolic acid and its glucuronide metabolite in small volumes of plasma from paediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15030883/),%,93.06,69846,DB00788,Naproxen
,15030883,extraction recovery,"The average extraction recovery from plasma was 93.06%, for MPA and 92.41% for MPAG.",Development of a high pressure liquid chromatography method for the determination of mycophenolic acid and its glucuronide metabolite in small volumes of plasma from paediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15030883/),%,92.41,69847,DB00788,Naproxen
,26839845,peak plasma concentration,"For the pure drug suspension, the peak plasma concentration was found as 8.499±0.029 μg/ml at 1.139±0.010 hours and the half-life was found to be 9.459±0.387 hours, whereas for the formulation the peak plasma concentration was found as 6.814±0.037 μg/ml at 8.042±0.069 hours and the half-life was found to be 19.657±0.359 hours.",Pharmacokinetic Parameters Determination and In Vitro-In Vivo Correlation of Ileocolonic-Targeted pH-Responsive Coated Mini-Tablets of Naproxen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26839845/),[μg] / [ml],8.499,78756,DB00788,Naproxen
,26839845,half-life,"For the pure drug suspension, the peak plasma concentration was found as 8.499±0.029 μg/ml at 1.139±0.010 hours and the half-life was found to be 9.459±0.387 hours, whereas for the formulation the peak plasma concentration was found as 6.814±0.037 μg/ml at 8.042±0.069 hours and the half-life was found to be 19.657±0.359 hours.",Pharmacokinetic Parameters Determination and In Vitro-In Vivo Correlation of Ileocolonic-Targeted pH-Responsive Coated Mini-Tablets of Naproxen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26839845/),h,9.459,78757,DB00788,Naproxen
,26839845,peak plasma concentration,"For the pure drug suspension, the peak plasma concentration was found as 8.499±0.029 μg/ml at 1.139±0.010 hours and the half-life was found to be 9.459±0.387 hours, whereas for the formulation the peak plasma concentration was found as 6.814±0.037 μg/ml at 8.042±0.069 hours and the half-life was found to be 19.657±0.359 hours.",Pharmacokinetic Parameters Determination and In Vitro-In Vivo Correlation of Ileocolonic-Targeted pH-Responsive Coated Mini-Tablets of Naproxen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26839845/),[μg] / [ml],6.814,78758,DB00788,Naproxen
,26839845,half-life,"For the pure drug suspension, the peak plasma concentration was found as 8.499±0.029 μg/ml at 1.139±0.010 hours and the half-life was found to be 9.459±0.387 hours, whereas for the formulation the peak plasma concentration was found as 6.814±0.037 μg/ml at 8.042±0.069 hours and the half-life was found to be 19.657±0.359 hours.",Pharmacokinetic Parameters Determination and In Vitro-In Vivo Correlation of Ileocolonic-Targeted pH-Responsive Coated Mini-Tablets of Naproxen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26839845/),h,19.657,78759,DB00788,Naproxen
,1127135,half-life,"The mean half-life of the drug in man is 13 hours, close to ideal for twice-daily administration.",Naproxen metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1127135/),h,13,80169,DB00788,Naproxen
,7787132,relative bioavailability,"The relative bioavailability of ibuprofen and naproxen, following oral administration of ibudice and napdice, was 96% and 74%, respectively, and the rate of absorption was not significantly different from that obtained following oral dosing of the parent compound.",Pharmacokinetic analysis of diethylcarbonate prodrugs of ibuprofen and naproxen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787132/),%,96,83137,DB00788,Naproxen
,7787132,relative bioavailability,"The relative bioavailability of ibuprofen and naproxen, following oral administration of ibudice and napdice, was 96% and 74%, respectively, and the rate of absorption was not significantly different from that obtained following oral dosing of the parent compound.",Pharmacokinetic analysis of diethylcarbonate prodrugs of ibuprofen and naproxen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787132/),%,74,83138,DB00788,Naproxen
,3680592,mean absorption time,"The mean absorption time of naproxen averaged 8.4 hours for the 750-mg controlled-release tablet and 9.2 hours for the 1,000-mg controlled-release tablet.",A multiple-dose pharmacokinetic comparison of naproxen as a once-daily controlled-release tablet and a twice-daily conventional tablet. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680592/),h,8.4,84322,DB00788,Naproxen
,3680592,mean absorption time,"The mean absorption time of naproxen averaged 8.4 hours for the 750-mg controlled-release tablet and 9.2 hours for the 1,000-mg controlled-release tablet.",A multiple-dose pharmacokinetic comparison of naproxen as a once-daily controlled-release tablet and a twice-daily conventional tablet. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680592/),h,9.2,84323,DB00788,Naproxen
,3259332,total through naproxen concentration,"At steady state, the median total through naproxen concentration was 50.5 mg/l in the elderly and 62.7 in the young (p = 0.08); the unbound concentration was 58 micrograms/l and 44 micrograms/l, respectively (p = 0.06).",Steady state pharmacokinetics of naproxen in elderly rheumatics compared with young volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3259332/),[mg] / [l],50.5,86035,DB00788,Naproxen
,3259332,total through naproxen concentration,"At steady state, the median total through naproxen concentration was 50.5 mg/l in the elderly and 62.7 in the young (p = 0.08); the unbound concentration was 58 micrograms/l and 44 micrograms/l, respectively (p = 0.06).",Steady state pharmacokinetics of naproxen in elderly rheumatics compared with young volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3259332/),,62.7,86036,DB00788,Naproxen
,3259332,unbound concentration,"At steady state, the median total through naproxen concentration was 50.5 mg/l in the elderly and 62.7 in the young (p = 0.08); the unbound concentration was 58 micrograms/l and 44 micrograms/l, respectively (p = 0.06).",Steady state pharmacokinetics of naproxen in elderly rheumatics compared with young volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3259332/),[μg] / [l],58,86037,DB00788,Naproxen
,3259332,unbound concentration,"At steady state, the median total through naproxen concentration was 50.5 mg/l in the elderly and 62.7 in the young (p = 0.08); the unbound concentration was 58 micrograms/l and 44 micrograms/l, respectively (p = 0.06).",Steady state pharmacokinetics of naproxen in elderly rheumatics compared with young volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3259332/),[μg] / [l],44,86038,DB00788,Naproxen
,8110026,elimination half-life,"The first one, phenylbutazone, is characterized by a fairly short elimination half-life (3-6 hours) in dogs, whereas the other one, naproxen, has an average half-life of 67 hours in this species.",Plasma and tissue kinetics of phenylbutazone and naproxen in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8110026/),h,3-6,86812,DB00788,Naproxen
,8110026,half-life,"The first one, phenylbutazone, is characterized by a fairly short elimination half-life (3-6 hours) in dogs, whereas the other one, naproxen, has an average half-life of 67 hours in this species.",Plasma and tissue kinetics of phenylbutazone and naproxen in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8110026/),h,67,86813,DB00788,Naproxen
,8110026,Plasma peak concentrations,Plasma peak concentrations of 49-75 micrograms/ml were reached.,Plasma and tissue kinetics of phenylbutazone and naproxen in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8110026/),[μg] / [ml],49-75,86814,DB00788,Naproxen
,8110026,half-life,"Due to a considerably longer half-life in the exudate than in plasma (7.3-18 hours), the concentration in the exudate exceeded that in plasma at about 20 hours.",Plasma and tissue kinetics of phenylbutazone and naproxen in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8110026/),h,7.3-18,86815,DB00788,Naproxen
,16372823,acid dissociation constant [pKa],"Lumiracoxib possesses a carboxylic acid group that makes it weakly acidic (acid dissociation constant [pKa] 4.7), distinguishing it from other selective COX-2 inhibitors.",Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),,4.7,89509,DB00788,Naproxen
,16372823,oral bioavailability,Lumiracoxib has good oral bioavailability (74%).,Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),%,74,89510,DB00788,Naproxen
,16372823,elimination half-life,Lumiracoxib has a short elimination half-life from plasma (mean 4 hours) and demonstrates dose-proportional plasma pharmacokinetics with no accumulation during multiple dosing.,Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),h,4,89511,DB00788,Naproxen
,6885201,Cmax,"Rapid absorption, with most Cmax values from 50-60 micrograms/ml reached within 1.5-3 h, was found for both tablet formulations.",Pharmacokinetics of naproxen after oral administration of two tablet formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6885201/),[μg] / [ml],50-60,90248,DB00788,Naproxen
,6885201,relative bioavailability,No significant difference was found in the rate and extent of absorption between the two formulations: the relative bioavailability of tablet I compared to tablet II was 1.05 +/- 0.21 (mean +/- SD).,Pharmacokinetics of naproxen after oral administration of two tablet formulations in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6885201/),,1.05,90249,DB00788,Naproxen
,21536505,absolute recovery,"The principal advantage of this LC-MS/MS method is the simultaneous achievement of high absolute recovery (90.0±3.6%), acceptable sensitivity (lower limit of quantitation of 0.100 μg/mL), high inter-day precision (CV≤9.4%), high analytical recovery (between 94.4 and 103.1%), and excellent linearity over the concentration range 0.100-50.0 μg/mL (r(2)≥0.998) combined with a short run time of only 2 min.","An LC-MS/MS procedure for the quantification of naproxen in human plasma: development, validation, comparison with other methods, and application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21536505/),%,90.0,91732,DB00788,Naproxen
,2328562,systemic clearance,"In twelve patients who completed the study, methotrexate systemic clearance was not statistically different with naproxen (103.3 +/- 35.0 ml/min) versus without naproxen (113.4 +/- 48.3 ml/min; p = 0.37).",Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328562/),[ml] / [min],103.3,91779,DB00788,Naproxen
,2328562,systemic clearance,"In twelve patients who completed the study, methotrexate systemic clearance was not statistically different with naproxen (103.3 +/- 35.0 ml/min) versus without naproxen (113.4 +/- 48.3 ml/min; p = 0.37).",Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328562/),[ml] / [min],113.4,91780,DB00788,Naproxen
,2328562,Oral clearance,Oral clearance of methotrexate was not statistically different with naproxen (161.7 +/- 55.0 ml/min) versus without naproxen (176.7 +/- 68.3 ml/min; p = 0.14).,Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328562/),[ml] / [min],161.7,91781,DB00788,Naproxen
,2328562,Oral clearance,Oral clearance of methotrexate was not statistically different with naproxen (161.7 +/- 55.0 ml/min) versus without naproxen (176.7 +/- 68.3 ml/min; p = 0.14).,Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328562/),[ml] / [min],176.7,91782,DB00788,Naproxen
,17920584,IC(50),"CS-706 selectively inhibited COX-2 in a human whole blood assay with an IC(50) of 0.31 microM, compared with an IC(50) of 2.2 microM for COX-1.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),μM,0.31,94872,DB00788,Naproxen
,17920584,IC(50),"CS-706 selectively inhibited COX-2 in a human whole blood assay with an IC(50) of 0.31 microM, compared with an IC(50) of 2.2 microM for COX-1.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),μM,2.2,94873,DB00788,Naproxen
,17920584,ID(50),"In an adjuvant-induced arthritic model in rats, CS-706 suppressed foot swelling prophylactically with an ID(50) of 0.10 mg/kg/day, and decreased foot swelling in the established arthritis therapeutically in a dose range of 0.040 to 1.0 mg/kg/day.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),[mg] / [d·kg],0.10,94874,DB00788,Naproxen
less,3410597,unbound fraction,"The unbound fraction (less than 1% of total naproxen) showed concentration dependency; in the elderly, a larger unbound fraction was found.",Pharmacokinetics of high-dosage naproxen in elderly patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410597/),%,1,95430,DB00788,Naproxen
,3410597,clearance of unbound drug,"Pharmacokinetic differences between the elderly and the young may be explained by a lower serum albumin concentration in the aged, together with a decrement in binding affinity of naproxen to albumin; moreover, the clearance of unbound drug was significantly reduced in the elderly (281 +/- 96 l/h) as compared with the young (713 +/- 164 l/h).",Pharmacokinetics of high-dosage naproxen in elderly patients. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410597/),[l] / [h],281,95431,DB00788,Naproxen
,3410597,clearance of unbound drug,"Pharmacokinetic differences between the elderly and the young may be explained by a lower serum albumin concentration in the aged, together with a decrement in binding affinity of naproxen to albumin; moreover, the clearance of unbound drug was significantly reduced in the elderly (281 +/- 96 l/h) as compared with the young (713 +/- 164 l/h).",Pharmacokinetics of high-dosage naproxen in elderly patients. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410597/),[l] / [h],713,95432,DB00788,Naproxen
,21324753,flow rate,"The method showed adequate separation for rosuvastatin and atorvastatin and best resolution was achieved with Brownlee analytical C18 column (150×4.6 mm, 5 μm) using methanol-water (68:32, v/v; pH adjusted to 3.0 with trifluoroacetic acid) as a mobile phase at a flow rate of 1.5 ml/min and wavelength of 241 nm.","Simultaneous determination of rosuvastatin and atorvastatin in human serum using RP-HPLC/UV detection: method development, validation and optimization of various experimental parameters. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21324753/),[ml] / [min],1.5,95580,DB00788,Naproxen
,32780750,injection flow,"Separation of naproxen and its major metabolic products will be performed using a Shim-Pack XR-ODS 75Lx2.0 column and C18 pre-column (Shimadzu, Kyoto, Japan) at 40°C using a mixture of methanol and 10 mM ammonium acetate (70:30, v/v) with an injection flow of 0.3 mL/min.",Simultaneous separation of naproxen and 6-O-desmethylnaproxen metabolite in saliva samples by liquid chromatography-tandem mass spectrometry: Pharmacokinetic study of naproxen alone and associated with esomeprazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32780750/),[ml] / [min],0.3,96951,DB00788,Naproxen
,32780750,total analytical run time,The total analytical run time will be 5 min.,Simultaneous separation of naproxen and 6-O-desmethylnaproxen metabolite in saliva samples by liquid chromatography-tandem mass spectrometry: Pharmacokinetic study of naproxen alone and associated with esomeprazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32780750/),min,5,96952,DB00788,Naproxen
,8352821,t1/2,"In non-intoxicated rats t1/2 was 5.31 +/- 0.90 h, Vd was 0.21 +/- 0.01 l.kg-1, Cl was 17 +/- 5 ml.h-1.kg-1, AUC was 354.4 +/- 8.8 micrograms.h.ml-1 and 99.18 +/- 0.09% of naproxen was bound to plasma proteins.",Pharmacokinetics and pharmacodynamics of naproxen in acute experimental hepatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352821/),h,5.31,98925,DB00788,Naproxen
,8352821,Vd,"In non-intoxicated rats t1/2 was 5.31 +/- 0.90 h, Vd was 0.21 +/- 0.01 l.kg-1, Cl was 17 +/- 5 ml.h-1.kg-1, AUC was 354.4 +/- 8.8 micrograms.h.ml-1 and 99.18 +/- 0.09% of naproxen was bound to plasma proteins.",Pharmacokinetics and pharmacodynamics of naproxen in acute experimental hepatitis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352821/),[l] / [kg],0.21,98926,DB00788,Naproxen
,8352821,Cl,"In non-intoxicated rats t1/2 was 5.31 +/- 0.90 h, Vd was 0.21 +/- 0.01 l.kg-1, Cl was 17 +/- 5 ml.h-1.kg-1, AUC was 354.4 +/- 8.8 micrograms.h.ml-1 and 99.18 +/- 0.09% of naproxen was bound to plasma proteins.",Pharmacokinetics and pharmacodynamics of naproxen in acute experimental hepatitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352821/),[ml] / [h·kg],17,98927,DB00788,Naproxen
,8352821,AUC,"In non-intoxicated rats t1/2 was 5.31 +/- 0.90 h, Vd was 0.21 +/- 0.01 l.kg-1, Cl was 17 +/- 5 ml.h-1.kg-1, AUC was 354.4 +/- 8.8 micrograms.h.ml-1 and 99.18 +/- 0.09% of naproxen was bound to plasma proteins.",Pharmacokinetics and pharmacodynamics of naproxen in acute experimental hepatitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352821/),[h·μg] / [ml],354.4,98928,DB00788,Naproxen
,8352821,t1/2,"Naproxen t1/2 was increased to 11.9 +/- 1.2 h but Vd did not change significantly, therefore clearance was reduced to 37%.",Pharmacokinetics and pharmacodynamics of naproxen in acute experimental hepatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352821/),h,11.9,98929,DB00788,Naproxen
,8352821,t1/2,"At day 3 liver function and naproxen pharmacokinetics exhibited a partial recovery, t1/2 was 6.59 +/- 0.92 h and clearance was 12.2 +/- 5 ml.h-1.kg-1 being not significantly different from controls; notwithstanding AUC was still significantly different from that of non-intoxicated rats.",Pharmacokinetics and pharmacodynamics of naproxen in acute experimental hepatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352821/),h,6.59,98930,DB00788,Naproxen
,8352821,clearance,"At day 3 liver function and naproxen pharmacokinetics exhibited a partial recovery, t1/2 was 6.59 +/- 0.92 h and clearance was 12.2 +/- 5 ml.h-1.kg-1 being not significantly different from controls; notwithstanding AUC was still significantly different from that of non-intoxicated rats.",Pharmacokinetics and pharmacodynamics of naproxen in acute experimental hepatitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352821/),[ml] / [h·kg],12.2,98931,DB00788,Naproxen
,3317799,half-life,A pharmacokinetic study showed a half-life for tenoxicam of 45 h in synovial fluid when the half-life was 42 h in plasma.,Clinical experience with tenoxicam: a review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317799/),h,45,101536,DB00788,Naproxen
,3317799,half-life,A pharmacokinetic study showed a half-life for tenoxicam of 45 h in synovial fluid when the half-life was 42 h in plasma.,Clinical experience with tenoxicam: a review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317799/),h,42,101537,DB00788,Naproxen
,3317799,peak plasma levels,A single and multiple oral dose pharmacokinetic study of tenoxicam in the elderly showed no progressive accumulation with peak plasma levels of 2.6 micrograms/ml after the single dose and 12.4 micrograms/ml at steady state.,Clinical experience with tenoxicam: a review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317799/),[μg] / [ml],2.6,101538,DB00788,Naproxen
,3317799,peak plasma levels,A single and multiple oral dose pharmacokinetic study of tenoxicam in the elderly showed no progressive accumulation with peak plasma levels of 2.6 micrograms/ml after the single dose and 12.4 micrograms/ml at steady state.,Clinical experience with tenoxicam: a review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317799/),[μg] / [ml],12.4,101539,DB00788,Naproxen
,1262531,Plasma half-lives,Plasma half-lives after both formulations were identical 10 hr 15 min+/-25 min (S.D.).,Naproxen plasma levels in volunteers after single-dose administration by oral and rectal routes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1262531/),h,10,111112,DB00788,Naproxen
,1262531,Plasma half-lives,Plasma half-lives after both formulations were identical 10 hr 15 min+/-25 min (S.D.).,Naproxen plasma levels in volunteers after single-dose administration by oral and rectal routes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1262531/),min,15,111113,DB00788,Naproxen
,1262531,bioavailability,Determined by the AUC the bioavailability of naproxen in the suppositories was 94.8%+/-6.3% of the bioavailability of naproxen in the tablets.,Naproxen plasma levels in volunteers after single-dose administration by oral and rectal routes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1262531/),%,94.8,111114,DB00788,Naproxen
,7460481,Peak concentrations,"Peak concentrations of naproxen varied between 26 and 69 microgram/ml and half-lifes varied between 9.5 and 21.9 hr, mean = 16.4 hr +/- 4.4 (SD).",Relation of naproxen kinetics to effect on platelet prostaglandin release in men and dysmenorrheic women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460481/),[μg] / [ml],26 and 69,111712,DB00788,Naproxen
,7460481,half-lifes,"Peak concentrations of naproxen varied between 26 and 69 microgram/ml and half-lifes varied between 9.5 and 21.9 hr, mean = 16.4 hr +/- 4.4 (SD).",Relation of naproxen kinetics to effect on platelet prostaglandin release in men and dysmenorrheic women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460481/),h,16.4,111713,DB00788,Naproxen
exceeded,7460481,plasma protein binding,Naproxen plasma protein binding exceeded 99.9%.,Relation of naproxen kinetics to effect on platelet prostaglandin release in men and dysmenorrheic women. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460481/),%,99.9,111714,DB00788,Naproxen
,26257511,Cmax,"The Cmax (mean ± standard deviation) and AUC0-t (mean ± standard deviation) for naproxen in HCP1004 were 61.67 ± 15.16 µg/mL and 1,206.52 ± 166.46 h · µg/mL, respectively; in VIMOVO(®); these values were 61.85 ± 14.54 µg/mL and 1,211.44 ± 170.01 h · µg/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[μg] / [ml],61.67,113794,DB00788,Naproxen
,26257511,Cmax,"The Cmax (mean ± standard deviation) and AUC0-t (mean ± standard deviation) for naproxen in HCP1004 were 61.67 ± 15.16 µg/mL and 1,206.52 ± 166.46 h · µg/mL, respectively; in VIMOVO(®); these values were 61.85 ± 14.54 µg/mL and 1,211.44 ± 170.01 h · µg/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[μg] / [ml],61.85,113795,DB00788,Naproxen
,26257511,AUC0-t,"The Cmax (mean ± standard deviation) and AUC0-t (mean ± standard deviation) for naproxen in HCP1004 were 61.67 ± 15.16 µg/mL and 1,206.52 ± 166.46 h · µg/mL, respectively; in VIMOVO(®); these values were 61.85 ± 14.54 µg/mL and 1,211.44 ± 170.01 h · µg/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[h·μg] / [ml],"1,206.52",113796,DB00788,Naproxen
,26257511,AUC0-t,"The Cmax (mean ± standard deviation) and AUC0-t (mean ± standard deviation) for naproxen in HCP1004 were 61.67 ± 15.16 µg/mL and 1,206.52 ± 166.46 h · µg/mL, respectively; in VIMOVO(®); these values were 61.85 ± 14.54 µg/mL and 1,211.44 ± 170.01 h · µg/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[h·μg] / [ml],"1,211.44",113797,DB00788,Naproxen
,26257511,Cmax,"The Cmax and AUC0-t for esomeprazole in HCP1004 were 658.21 ± 510.91 ng/mL and 1,109.11 ± 1,111.59 h · ng/mL, respectively; for VIMOVO(®), these values were 595.09 ± 364.23 ng/mL and 1,015.12 ± 952.98 h · ng/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[ng] / [ml],658.21,113798,DB00788,Naproxen
,26257511,Cmax,"The Cmax and AUC0-t for esomeprazole in HCP1004 were 658.21 ± 510.91 ng/mL and 1,109.11 ± 1,111.59 h · ng/mL, respectively; for VIMOVO(®), these values were 595.09 ± 364.23 ng/mL and 1,015.12 ± 952.98 h · ng/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[ng] / [ml],595.09,113799,DB00788,Naproxen
,26257511,AUC0-t,"The Cmax and AUC0-t for esomeprazole in HCP1004 were 658.21 ± 510.91 ng/mL and 1,109.11 ± 1,111.59 h · ng/mL, respectively; for VIMOVO(®), these values were 595.09 ± 364.23 ng/mL and 1,015.12 ± 952.98 h · ng/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[h·ng] / [ml],"1,109.11",113800,DB00788,Naproxen
,26257511,AUC0-t,"The Cmax and AUC0-t for esomeprazole in HCP1004 were 658.21 ± 510.91 ng/mL and 1,109.11 ± 1,111.59 h · ng/mL, respectively; for VIMOVO(®), these values were 595.09 ± 364.23 ng/mL and 1,015.12 ± 952.98 h · ng/mL, respectively.",Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257511/),[h·ng] / [ml],"1,015.12",113801,DB00788,Naproxen
,3335121,apparent volume of distribution,"Total naproxen concentrations were significantly lower in active disease, together with a larger apparent volume of distribution (10.6 +/- 1.8 L vs. 8.4 +/- 1.3 L; P less than 0.05) and total body clearance (0.79 +/- 1.8 L/hr vs. 0.59 +/- 0.14 L/hr; P less than 0.001).",Naproxen kinetics and disease activity in rheumatoid arthritis: a within-patient study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335121/),l,10.6,114467,DB00788,Naproxen
,3335121,apparent volume of distribution,"Total naproxen concentrations were significantly lower in active disease, together with a larger apparent volume of distribution (10.6 +/- 1.8 L vs. 8.4 +/- 1.3 L; P less than 0.05) and total body clearance (0.79 +/- 1.8 L/hr vs. 0.59 +/- 0.14 L/hr; P less than 0.001).",Naproxen kinetics and disease activity in rheumatoid arthritis: a within-patient study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335121/),l,8.4,114468,DB00788,Naproxen
,3335121,total body clearance,"Total naproxen concentrations were significantly lower in active disease, together with a larger apparent volume of distribution (10.6 +/- 1.8 L vs. 8.4 +/- 1.3 L; P less than 0.05) and total body clearance (0.79 +/- 1.8 L/hr vs. 0.59 +/- 0.14 L/hr; P less than 0.001).",Naproxen kinetics and disease activity in rheumatoid arthritis: a within-patient study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335121/),[l] / [h],0.79,114469,DB00788,Naproxen
,3335121,total body clearance,"Total naproxen concentrations were significantly lower in active disease, together with a larger apparent volume of distribution (10.6 +/- 1.8 L vs. 8.4 +/- 1.3 L; P less than 0.05) and total body clearance (0.79 +/- 1.8 L/hr vs. 0.59 +/- 0.14 L/hr; P less than 0.001).",Naproxen kinetics and disease activity in rheumatoid arthritis: a within-patient study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335121/),[l] / [h],0.59,114470,DB00788,Naproxen
,3335121,unbound clearance,The unbound clearance was found diminished during active disease (390 +/- 277 L/hr) in comparison with improvement (488 +/- 343 L/hr; P less than 0.05).,Naproxen kinetics and disease activity in rheumatoid arthritis: a within-patient study. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335121/),[l] / [h],390,114471,DB00788,Naproxen
,3335121,unbound clearance,The unbound clearance was found diminished during active disease (390 +/- 277 L/hr) in comparison with improvement (488 +/- 343 L/hr; P less than 0.05).,Naproxen kinetics and disease activity in rheumatoid arthritis: a within-patient study. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335121/),[l] / [h],488,114472,DB00788,Naproxen
,9356198,maximal effect,"The maximal effect lasted 12 and 36 h following 10 and 20 mg kg-1 doses, respectively.",Toxicokinetics of indomethacin-induced intestinal permeability in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356198/),h,12,116211,DB00788,Naproxen
,9356198,maximal effect,"The maximal effect lasted 12 and 36 h following 10 and 20 mg kg-1 doses, respectively.",Toxicokinetics of indomethacin-induced intestinal permeability in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356198/),h,36,116212,DB00788,Naproxen
,12408894,Recovery,Recovery of both enantiomers was in the range of 85-91%.,Determination of ketoprofen enantiomers in human serum by capillary zone electrophoresis: man pharmacokinetic studies after administration of rac-ketoprofen tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408894/),%,85-91,116320,DB00788,Naproxen
>,12408894,signal-to-noise baseline ratio (S/N),"The linear range of calibration curves was between 0.25 and 50 mg l(-1), with detection limit of 0.1 mg l(-1) (signal-to-noise baseline ratio (S/N) >4).",Determination of ketoprofen enantiomers in human serum by capillary zone electrophoresis: man pharmacokinetic studies after administration of rac-ketoprofen tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408894/),,4,116321,DB00788,Naproxen
,11745747,loss,"Naproxen, which was shown to have a similar in vivo loss by retrodialysis as flurbiprofen (71.5 +/- 0.9% and 71.0 +/- 0.8% respectively, n = 3), was used to continuously monitor probe recovery.",Validation of subcutaneous microdialysis sampling for pharmacokinetic studies of flurbiprofen in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745747/),%,71.5,120394,DB00788,Naproxen
,11745747,loss,"Naproxen, which was shown to have a similar in vivo loss by retrodialysis as flurbiprofen (71.5 +/- 0.9% and 71.0 +/- 0.8% respectively, n = 3), was used to continuously monitor probe recovery.",Validation of subcutaneous microdialysis sampling for pharmacokinetic studies of flurbiprofen in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745747/),%,71.0,120395,DB00788,Naproxen
,15900289,maximal,"Urinary sodium excretion was reduced in all active treatment groups (maximal reduction of approximately 11 mmol/h during normal sodium intake, P < .05 versus placebo for all groups).",Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900289/),,11,120422,DB00788,Naproxen
,15900289,maximal reduction,"In sodium-depleted subjects, the mean (SD) maximal reduction in GFR during 0 to 6 hours for 750 mg AZD3582, 1500 mg AZD3582, 50 mg rofecoxib, and 500 mg naproxen was 28.1 mL/min (13.5 mL/min), 33.7 mL/min (23.3 mL/min), 25.2 mL/min (29.2 mL/min), and 41.7 mL/min (30.7 mL/min), respectively, with a statistically significant difference between 500 mg naproxen and placebo.",Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900289/),[ml] / [min],28.1,120423,DB00788,Naproxen
,15900289,maximal reduction,"In sodium-depleted subjects, the mean (SD) maximal reduction in GFR during 0 to 6 hours for 750 mg AZD3582, 1500 mg AZD3582, 50 mg rofecoxib, and 500 mg naproxen was 28.1 mL/min (13.5 mL/min), 33.7 mL/min (23.3 mL/min), 25.2 mL/min (29.2 mL/min), and 41.7 mL/min (30.7 mL/min), respectively, with a statistically significant difference between 500 mg naproxen and placebo.",Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900289/),[ml] / [min],33.7,120424,DB00788,Naproxen
,15900289,maximal reduction,"In sodium-depleted subjects, the mean (SD) maximal reduction in GFR during 0 to 6 hours for 750 mg AZD3582, 1500 mg AZD3582, 50 mg rofecoxib, and 500 mg naproxen was 28.1 mL/min (13.5 mL/min), 33.7 mL/min (23.3 mL/min), 25.2 mL/min (29.2 mL/min), and 41.7 mL/min (30.7 mL/min), respectively, with a statistically significant difference between 500 mg naproxen and placebo.",Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900289/),[ml] / [min],25.2,120425,DB00788,Naproxen
,15900289,maximal reduction,"In sodium-depleted subjects, the mean (SD) maximal reduction in GFR during 0 to 6 hours for 750 mg AZD3582, 1500 mg AZD3582, 50 mg rofecoxib, and 500 mg naproxen was 28.1 mL/min (13.5 mL/min), 33.7 mL/min (23.3 mL/min), 25.2 mL/min (29.2 mL/min), and 41.7 mL/min (30.7 mL/min), respectively, with a statistically significant difference between 500 mg naproxen and placebo.",Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900289/),[ml] / [min],41.7,120426,DB00788,Naproxen
,2735334,maximal plasma concentration,"In the presence of food, maximal plasma concentration decreased from 10.7 to 6.3 micrograms/ml after single-dose administration and 12.1 to 8.0 micrograms/ml after multiple-dose administration.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),[μg] / [ml],10.7 to 6.3,121101,DB00788,Naproxen
,2735334,maximal plasma concentration,"In the presence of food, maximal plasma concentration decreased from 10.7 to 6.3 micrograms/ml after single-dose administration and 12.1 to 8.0 micrograms/ml after multiple-dose administration.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),[μg] / [ml],12.1 to 8.0,121102,DB00788,Naproxen
,2735334,time to reach maximal plasma concentration,"The time to reach maximal plasma concentration was also modified by food, increasing from 2.8 to 7.1 hours after single-dose and 2.8 to 7.6 hours after multiple-dose administration.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),h,2.8,121103,DB00788,Naproxen
,2735334,time to reach maximal plasma concentration,"The time to reach maximal plasma concentration was also modified by food, increasing from 2.8 to 7.1 hours after single-dose and 2.8 to 7.6 hours after multiple-dose administration.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),h,7,121104,DB00788,Naproxen
,2735334,time to reach maximal plasma concentration,"The time to reach maximal plasma concentration was also modified by food, increasing from 2.8 to 7.1 hours after single-dose and 2.8 to 7.6 hours after multiple-dose administration.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),h,2.8 to 7.6,121105,DB00788,Naproxen
over,2735334,bioavailability,Food caused a significant decrease in the bioavailability of ketoprofen (over 40 percent) following both single-dose (23.8 versus 13.1 micrograms.hour/ml) and multiple-dose (29.3 versus 16.8 micrograms.hour/ml) administration.,Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),%,40,121106,DB00788,Naproxen
,2735334,bioavailability,Food caused a significant decrease in the bioavailability of ketoprofen (over 40 percent) following both single-dose (23.8 versus 13.1 micrograms.hour/ml) and multiple-dose (29.3 versus 16.8 micrograms.hour/ml) administration.,Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),μ,23.8,121107,DB00788,Naproxen
,2735334,bioavailability,Food caused a significant decrease in the bioavailability of ketoprofen (over 40 percent) following both single-dose (23.8 versus 13.1 micrograms.hour/ml) and multiple-dose (29.3 versus 16.8 micrograms.hour/ml) administration.,Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),μ,13.1,121108,DB00788,Naproxen
,2735334,bioavailability,Food caused a significant decrease in the bioavailability of ketoprofen (over 40 percent) following both single-dose (23.8 versus 13.1 micrograms.hour/ml) and multiple-dose (29.3 versus 16.8 micrograms.hour/ml) administration.,Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),μ,29.3,121109,DB00788,Naproxen
,2735334,bioavailability,Food caused a significant decrease in the bioavailability of ketoprofen (over 40 percent) following both single-dose (23.8 versus 13.1 micrograms.hour/ml) and multiple-dose (29.3 versus 16.8 micrograms.hour/ml) administration.,Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),μ,16.8,121110,DB00788,Naproxen
,2735334,absorption rate constant,"Results obtained in group 3 showed that sucralfate reduced the absorption rate constant of naproxen, from 1.7 to 1.2 hours-1 and from 1.5 to 0.7 hour-1 following single- and multiple-dose administration, respectively.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),1/[h],1.7 to 1.2,121111,DB00788,Naproxen
,2735334,absorption rate constant,"Results obtained in group 3 showed that sucralfate reduced the absorption rate constant of naproxen, from 1.7 to 1.2 hours-1 and from 1.5 to 0.7 hour-1 following single- and multiple-dose administration, respectively.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),1/[h],1.5 to 0.7,121112,DB00788,Naproxen
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],527.00,122561,DB00788,Naproxen
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],269. 45,122562,DB00788,Naproxen
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],258.65,122563,DB00788,Naproxen
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],243.22,122564,DB00788,Naproxen
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],88.09,122565,DB00788,Naproxen
,18358504,IC(50),RIAA inhibited LPS-stimulated PGE(2) formation with >200-fold selectivity of COX-2 (IC(50)=1.3 microg/ml) over COX-1 (IC(50)>289 microg/ml).,"Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],1.3,123772,DB00788,Naproxen
>,18358504,IC(50),RIAA inhibited LPS-stimulated PGE(2) formation with >200-fold selectivity of COX-2 (IC(50)=1.3 microg/ml) over COX-1 (IC(50)>289 microg/ml).,"Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],289,123773,DB00788,Naproxen
,18358504,IC(50),"In support, we found RIAA showed minimal PGE(2) inhibition (IC(50)=21mug/ml) relative to celecoxib (IC(50)=0.024 microg/ml), aspirin (IC(50)=0.52 microg/ml) or ibuprofen (IC(50)=0.57 microg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively.","Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],21,123774,DB00788,Naproxen
,18358504,IC(50),"In support, we found RIAA showed minimal PGE(2) inhibition (IC(50)=21mug/ml) relative to celecoxib (IC(50)=0.024 microg/ml), aspirin (IC(50)=0.52 microg/ml) or ibuprofen (IC(50)=0.57 microg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively.","Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],0.024,123775,DB00788,Naproxen
,18358504,IC(50),"In support, we found RIAA showed minimal PGE(2) inhibition (IC(50)=21mug/ml) relative to celecoxib (IC(50)=0.024 microg/ml), aspirin (IC(50)=0.52 microg/ml) or ibuprofen (IC(50)=0.57 microg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively.","Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],0.52,123776,DB00788,Naproxen
,18358504,IC(50),"In support, we found RIAA showed minimal PGE(2) inhibition (IC(50)=21mug/ml) relative to celecoxib (IC(50)=0.024 microg/ml), aspirin (IC(50)=0.52 microg/ml) or ibuprofen (IC(50)=0.57 microg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively.","Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],0.57,123777,DB00788,Naproxen
,8314361,t1/2 beta,The mean t1/2 beta of naproxen in 6 subjects was 25.7 +/- 5.4 h (range 16 to 36).,"The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314361/),h,25.7,124746,DB00788,Naproxen
,8314361,t1/2 beta,"Cimetidine, ranitidine and famotidine all reduced significantly the t1/2 beta of naproxen by 50% from 25 h to 13 h and the t1/2 alpha from 4.0 h to 1.1 h.","The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314361/),h,25,124747,DB00788,Naproxen
,8314361,t1/2 beta,"Cimetidine, ranitidine and famotidine all reduced significantly the t1/2 beta of naproxen by 50% from 25 h to 13 h and the t1/2 alpha from 4.0 h to 1.1 h.","The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314361/),h,13,124748,DB00788,Naproxen
,8314361,t1/2 alpha,"Cimetidine, ranitidine and famotidine all reduced significantly the t1/2 beta of naproxen by 50% from 25 h to 13 h and the t1/2 alpha from 4.0 h to 1.1 h.","The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314361/),h,4.0,124749,DB00788,Naproxen
,8314361,t1/2 alpha,"Cimetidine, ranitidine and famotidine all reduced significantly the t1/2 beta of naproxen by 50% from 25 h to 13 h and the t1/2 alpha from 4.0 h to 1.1 h.","The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314361/),h,1.1,124750,DB00788,Naproxen
,3243931,total area under the plasma concentration-time curve,"The total area under the plasma concentration-time curve averaged 2221 micrograms.hr/mL in fasting participants and 2111 micrograms.hr/mL in postprandial participants; whereas the difference was statistically significant (P = .025), the 95% confidence intervals indicated equivalent values.",Absorption of naproxen controlled-release tablets in fasting and postprandial volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243931/),[h·μg] / [ml],2221,125139,DB00788,Naproxen
,3243931,total area under the plasma concentration-time curve,"The total area under the plasma concentration-time curve averaged 2221 micrograms.hr/mL in fasting participants and 2111 micrograms.hr/mL in postprandial participants; whereas the difference was statistically significant (P = .025), the 95% confidence intervals indicated equivalent values.",Absorption of naproxen controlled-release tablets in fasting and postprandial volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243931/),[h·μg] / [ml],2111,125140,DB00788,Naproxen
,3243931,peak plasma concentration,The peak plasma concentration was lower in the fasting state (63.1 micrograms/mL) than in the fed state (86.1 micrograms/mL) (P = .0001).,Absorption of naproxen controlled-release tablets in fasting and postprandial volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243931/),[μg] / [ml],63.1,125141,DB00788,Naproxen
,3243931,peak plasma concentration,The peak plasma concentration was lower in the fasting state (63.1 micrograms/mL) than in the fed state (86.1 micrograms/mL) (P = .0001).,Absorption of naproxen controlled-release tablets in fasting and postprandial volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243931/),[μg] / [ml],86.1,125142,DB00788,Naproxen
,3243931,mean absorption time,There were no statistically significant differences between fasting versus postprandial values for the mean absorption time (9.7 hr vs. 7.7 hr) or plasma half-life (17.3 hr vs. 17.6 hr).,Absorption of naproxen controlled-release tablets in fasting and postprandial volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243931/),h,9.7,125143,DB00788,Naproxen
,3243931,mean absorption time,There were no statistically significant differences between fasting versus postprandial values for the mean absorption time (9.7 hr vs. 7.7 hr) or plasma half-life (17.3 hr vs. 17.6 hr).,Absorption of naproxen controlled-release tablets in fasting and postprandial volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243931/),h,7.7,125144,DB00788,Naproxen
,3243931,plasma half-life,There were no statistically significant differences between fasting versus postprandial values for the mean absorption time (9.7 hr vs. 7.7 hr) or plasma half-life (17.3 hr vs. 17.6 hr).,Absorption of naproxen controlled-release tablets in fasting and postprandial volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243931/),h,17.3,125145,DB00788,Naproxen
,3243931,plasma half-life,There were no statistically significant differences between fasting versus postprandial values for the mean absorption time (9.7 hr vs. 7.7 hr) or plasma half-life (17.3 hr vs. 17.6 hr).,Absorption of naproxen controlled-release tablets in fasting and postprandial volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243931/),h,17.6,125146,DB00788,Naproxen
,7233492,area under the curve,"Coadministration of naproxen with Mylanta in the single-dose experiment did not significantly affect the area under the curve (579 vs. 580 microgram/ml X hr with and without Mylanta, respectively), time to peak serum concentration (2.5 vs. 2.6 hr), peak serum concentration (37.2 vs. 34.8 microgram/ml) or plasma half-life (16.1 vs. 16.4 hr).",Effect of Mylanta on naproxen bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7233492/),[μg] / [h·ml],579,132691,DB00788,Naproxen
,7233492,area under the curve,"Coadministration of naproxen with Mylanta in the single-dose experiment did not significantly affect the area under the curve (579 vs. 580 microgram/ml X hr with and without Mylanta, respectively), time to peak serum concentration (2.5 vs. 2.6 hr), peak serum concentration (37.2 vs. 34.8 microgram/ml) or plasma half-life (16.1 vs. 16.4 hr).",Effect of Mylanta on naproxen bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7233492/),[μg] / [h·ml],580,132692,DB00788,Naproxen
,7233492,time to peak serum concentration,"Coadministration of naproxen with Mylanta in the single-dose experiment did not significantly affect the area under the curve (579 vs. 580 microgram/ml X hr with and without Mylanta, respectively), time to peak serum concentration (2.5 vs. 2.6 hr), peak serum concentration (37.2 vs. 34.8 microgram/ml) or plasma half-life (16.1 vs. 16.4 hr).",Effect of Mylanta on naproxen bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7233492/),h,2.5,132693,DB00788,Naproxen
,7233492,time to peak serum concentration,"Coadministration of naproxen with Mylanta in the single-dose experiment did not significantly affect the area under the curve (579 vs. 580 microgram/ml X hr with and without Mylanta, respectively), time to peak serum concentration (2.5 vs. 2.6 hr), peak serum concentration (37.2 vs. 34.8 microgram/ml) or plasma half-life (16.1 vs. 16.4 hr).",Effect of Mylanta on naproxen bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7233492/),h,2.6,132694,DB00788,Naproxen
,7233492,peak serum concentration,"Coadministration of naproxen with Mylanta in the single-dose experiment did not significantly affect the area under the curve (579 vs. 580 microgram/ml X hr with and without Mylanta, respectively), time to peak serum concentration (2.5 vs. 2.6 hr), peak serum concentration (37.2 vs. 34.8 microgram/ml) or plasma half-life (16.1 vs. 16.4 hr).",Effect of Mylanta on naproxen bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7233492/),[μg] / [ml],37.2,132695,DB00788,Naproxen
,7233492,peak serum concentration,"Coadministration of naproxen with Mylanta in the single-dose experiment did not significantly affect the area under the curve (579 vs. 580 microgram/ml X hr with and without Mylanta, respectively), time to peak serum concentration (2.5 vs. 2.6 hr), peak serum concentration (37.2 vs. 34.8 microgram/ml) or plasma half-life (16.1 vs. 16.4 hr).",Effect of Mylanta on naproxen bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7233492/),[μg] / [ml],34.8,132696,DB00788,Naproxen
,7233492,plasma half-life,"Coadministration of naproxen with Mylanta in the single-dose experiment did not significantly affect the area under the curve (579 vs. 580 microgram/ml X hr with and without Mylanta, respectively), time to peak serum concentration (2.5 vs. 2.6 hr), peak serum concentration (37.2 vs. 34.8 microgram/ml) or plasma half-life (16.1 vs. 16.4 hr).",Effect of Mylanta on naproxen bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7233492/),h,16.1,132697,DB00788,Naproxen
,7233492,plasma half-life,"Coadministration of naproxen with Mylanta in the single-dose experiment did not significantly affect the area under the curve (579 vs. 580 microgram/ml X hr with and without Mylanta, respectively), time to peak serum concentration (2.5 vs. 2.6 hr), peak serum concentration (37.2 vs. 34.8 microgram/ml) or plasma half-life (16.1 vs. 16.4 hr).",Effect of Mylanta on naproxen bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7233492/),h,16.4,132698,DB00788,Naproxen
,7233492,trough level naproxen concentrations at steady state,There was no significant difference between trough level naproxen concentrations at steady state (29.6 microgram/ml with Mylanta vs. 30.7 microgram/ml without Mylanta).,Effect of Mylanta on naproxen bioavailability. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7233492/),[μg] / [ml],29.6,132699,DB00788,Naproxen
,7233492,trough level naproxen concentrations at steady state,There was no significant difference between trough level naproxen concentrations at steady state (29.6 microgram/ml with Mylanta vs. 30.7 microgram/ml without Mylanta).,Effect of Mylanta on naproxen bioavailability. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7233492/),[μg] / [ml],30.7,132700,DB00788,Naproxen
,3403096,elimination half-life,The elimination half-life is 15.2 +/- 2.6 h.,The pharmacokinetic profile of naproxen suppository in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403096/),h,15.2,132780,DB00788,Naproxen
,3403096,half-lives,"Ten out of 22 subjects show biphasic elimination kinetics with half-lives of 7 and 15 h, respectively.",The pharmacokinetic profile of naproxen suppository in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403096/),h,7,132781,DB00788,Naproxen
,3403096,half-lives,"Ten out of 22 subjects show biphasic elimination kinetics with half-lives of 7 and 15 h, respectively.",The pharmacokinetic profile of naproxen suppository in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403096/),h,15,132782,DB00788,Naproxen
,19878101,half-life,N-acetyl-DL-tryptophan had a half-life of approximately 30 min.,Infusions of albumin increase free fraction of naproxen in healthy volunteers: a randomized crossover study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878101/),min,30,133085,DB00788,Naproxen
<,19878101,half-life,The half-life of caprylate was <15 min.,Infusions of albumin increase free fraction of naproxen in healthy volunteers: a randomized crossover study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878101/),min,15,133086,DB00788,Naproxen
,3393838,half-life,"The half-life is longer in the synovial fluid than in the serum, 23 hours versus 17 hours.","[Serum, synovial and intra-articular pharmacokinetics of naproxen after one-gram oral administration in patients with rheumatoid polyarthritis]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3393838/),h,23,134337,DB00788,Naproxen
,3393838,half-life,"The half-life is longer in the synovial fluid than in the serum, 23 hours versus 17 hours.","[Serum, synovial and intra-articular pharmacokinetics of naproxen after one-gram oral administration in patients with rheumatoid polyarthritis]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3393838/),h,17,134338,DB00788,Naproxen
,7697688,plasma half-life,"The plasma half-life of naproxen averaged 16.3 and 16.9 hours following EC naproxen and standard naproxen treatments, respectively.",Steady-state pharmacokinetics of enteric-coated naproxen tablets compared with standard naproxen tablets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7697688/),h,16.3,134787,DB00788,Naproxen
,7697688,plasma half-life,"The plasma half-life of naproxen averaged 16.3 and 16.9 hours following EC naproxen and standard naproxen treatments, respectively.",Steady-state pharmacokinetics of enteric-coated naproxen tablets compared with standard naproxen tablets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7697688/),h,16.9,134788,DB00788,Naproxen
,7697688,time to maximum plasma concentration (Tmax),"Mean time to maximum plasma concentration (Tmax) was greater for EC naproxen than for standard naproxen (4.0 vs 1.9 hours), while the maximum observed plasma concentration (Cmax) was slightly, but not significantly, smaller (94.9 vs 97.4 micrograms/mL, respectively).",Steady-state pharmacokinetics of enteric-coated naproxen tablets compared with standard naproxen tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7697688/),h,4.0,134789,DB00788,Naproxen
,7697688,time to maximum plasma concentration (Tmax),"Mean time to maximum plasma concentration (Tmax) was greater for EC naproxen than for standard naproxen (4.0 vs 1.9 hours), while the maximum observed plasma concentration (Cmax) was slightly, but not significantly, smaller (94.9 vs 97.4 micrograms/mL, respectively).",Steady-state pharmacokinetics of enteric-coated naproxen tablets compared with standard naproxen tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7697688/),h,1.9,134790,DB00788,Naproxen
,7697688,maximum observed plasma concentration (Cmax),"Mean time to maximum plasma concentration (Tmax) was greater for EC naproxen than for standard naproxen (4.0 vs 1.9 hours), while the maximum observed plasma concentration (Cmax) was slightly, but not significantly, smaller (94.9 vs 97.4 micrograms/mL, respectively).",Steady-state pharmacokinetics of enteric-coated naproxen tablets compared with standard naproxen tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7697688/),[μg] / [ml],94.9,134791,DB00788,Naproxen
,7697688,maximum observed plasma concentration (Cmax),"Mean time to maximum plasma concentration (Tmax) was greater for EC naproxen than for standard naproxen (4.0 vs 1.9 hours), while the maximum observed plasma concentration (Cmax) was slightly, but not significantly, smaller (94.9 vs 97.4 micrograms/mL, respectively).",Steady-state pharmacokinetics of enteric-coated naproxen tablets compared with standard naproxen tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7697688/),[μg] / [ml],97.4,134792,DB00788,Naproxen
,7697688,plasma concentration (Cave),"The mean values for average plasma concentration (Cave) and minimum plasma concentration for EC naproxen were 70.4 and 60.6 micrograms/mL, respectively, compared with 63.9 and 44.1 micrograms/mL for standard naproxen.",Steady-state pharmacokinetics of enteric-coated naproxen tablets compared with standard naproxen tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7697688/),[μg] / [ml],70.4,134793,DB00788,Naproxen
,7697688,plasma concentration (Cave),"The mean values for average plasma concentration (Cave) and minimum plasma concentration for EC naproxen were 70.4 and 60.6 micrograms/mL, respectively, compared with 63.9 and 44.1 micrograms/mL for standard naproxen.",Steady-state pharmacokinetics of enteric-coated naproxen tablets compared with standard naproxen tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7697688/),[μg] / [ml],63.9,134794,DB00788,Naproxen
,7697688,minimum plasma concentration,"The mean values for average plasma concentration (Cave) and minimum plasma concentration for EC naproxen were 70.4 and 60.6 micrograms/mL, respectively, compared with 63.9 and 44.1 micrograms/mL for standard naproxen.",Steady-state pharmacokinetics of enteric-coated naproxen tablets compared with standard naproxen tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7697688/),[μg] / [ml],60.6,134795,DB00788,Naproxen
,7697688,minimum plasma concentration,"The mean values for average plasma concentration (Cave) and minimum plasma concentration for EC naproxen were 70.4 and 60.6 micrograms/mL, respectively, compared with 63.9 and 44.1 micrograms/mL for standard naproxen.",Steady-state pharmacokinetics of enteric-coated naproxen tablets compared with standard naproxen tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7697688/),[μg] / [ml],44.1,134796,DB00788,Naproxen
,7697688,area under the plasma concentration-time curve (AUC),"The mean plasma fluctuation about the mean was greater for standard naproxen than for EC naproxen (85.3% vs 49.3%), while the mean area under the plasma concentration-time curve (AUC) was smaller for standard naproxen (766.8 vs 845.0 micrograms x h/mL).",Steady-state pharmacokinetics of enteric-coated naproxen tablets compared with standard naproxen tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7697688/),[h·μg] / [ml],766.8,134797,DB00788,Naproxen
,7697688,area under the plasma concentration-time curve (AUC),"The mean plasma fluctuation about the mean was greater for standard naproxen than for EC naproxen (85.3% vs 49.3%), while the mean area under the plasma concentration-time curve (AUC) was smaller for standard naproxen (766.8 vs 845.0 micrograms x h/mL).",Steady-state pharmacokinetics of enteric-coated naproxen tablets compared with standard naproxen tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7697688/),[h·μg] / [ml],845.0,134798,DB00788,Naproxen
,1807089,Minimal detectable concentration,Minimal detectable concentration of serum piroxicam by using HPLC reported in literature was mostly around 50 ng.,[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),ng,50,135527,DB00788,Naproxen
,1807089,detection limit,"A new HPLC method providing a detection limit of 0.75 ng, sensitive enough to quantify low concentrations of serum piroxicam down to 5 ng.",[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),ng,0.75,135528,DB00788,Naproxen
,1807089,flow rate,A mixture of methanol and ammonium acetate 0.1 mol.L-1 (1:0.9 vol.vol-1) was selected as mobile phase with a flow rate of 1 ml.min-1. 0.025% tetramethyl ethylene diamine was added to ammonium acetate solution and adjusted to pH 4.5 with citric acid before mixing.,[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),[ml] / [min],1,135529,DB00788,Naproxen
,1807089,recoveries,"The within-day and day-to-day precisions (CV) of this method were 2.88% and 2.89% respectively, with average recoveries of 96.0-102.4% (10-5,000 ng.ml-1).",[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),%,96.0-102.4,135530,DB00788,Naproxen
,1807089,recoveries,"The within-day and day-to-day precisions (CV) of this method were 2.88% and 2.89% respectively, with average recoveries of 96.0-102.4% (10-5,000 ng.ml-1).",[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),[ng] / [ml],"10-5,000",135531,DB00788,Naproxen
less,3552584,Volume of distribution,Volume of distribution is mostly low (less than 0.2 L/kg) and protein binding is high (usually 95 to 99%).,Non-steroidal anti-inflammatory analgesics other than salicylates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),[l] / [kg],0.2,136228,DB00788,Naproxen
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,2 to 5,136229,DB00788,Naproxen
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,20,136230,DB00788,Naproxen
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,10,136231,DB00788,Naproxen
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,12-15,136232,DB00788,Naproxen
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,16,136233,DB00788,Naproxen
,3552584,half-life,"Piroxicam has the longest half-life, averaging 45 hours.",Non-steroidal anti-inflammatory analgesics other than salicylates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,45,136234,DB00788,Naproxen
,18840026,apparent volume of distribution,"Etoricoxib is extensively protein bound, primarily to plasma albumin, and has an apparent volume of distribution of 120 L in humans.",Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840026/),l,120,139735,DB00788,Naproxen
,18840026,elimination half-life,The elimination half-life of approximately 20 hours in healthy subjects enables once-daily dosing.,Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840026/),h,20,139736,DB00788,Naproxen
<,10701434,run times,"The method has a lower limit of quantification (LLOQ) adequate for sensitive pharmacokinetic studies ( < or = 0.05 microg/ml), has run times of < or = 15 min, and uses aliquot volumes adequate for pediatric studies (0.25 ml).","A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),min,15,140499,DB00788,Naproxen
,10701434,lambda(ex),Detection and quantification of ganciclovir is by fluorescence (lambda(ex) = 278 nm; lambda(em) = 380 nm).,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),,278,140500,DB00788,Naproxen
,10701434,lambda(em),Detection and quantification of ganciclovir is by fluorescence (lambda(ex) = 278 nm; lambda(em) = 380 nm).,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),,380,140501,DB00788,Naproxen
<,10701434,% C.V.,All intra- and inter-assay % C.V. values were < 8%; all recoveries (accuracy) were within 7% of nominal values.,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),%,8,140502,DB00788,Naproxen
,15761938,In,"In vivo recoveries of both probes, determined by using naproxen as retrodialysis calibrator, were 26.0 +/- 0.3 and 72.9 +/- 0.7% for dermal and subcutaneous probe, respectively.",Study of the percutaneous penetration of flurbiprofen by cutaneous and subcutaneous microdialysis after iontophoretic delivery in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761938/),%,26.0,142390,DB00788,Naproxen
,15761938,recoveries,"In vivo recoveries of both probes, determined by using naproxen as retrodialysis calibrator, were 26.0 +/- 0.3 and 72.9 +/- 0.7% for dermal and subcutaneous probe, respectively.",Study of the percutaneous penetration of flurbiprofen by cutaneous and subcutaneous microdialysis after iontophoretic delivery in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761938/),%,26.0,142391,DB00788,Naproxen
,15761938,recoveries,"In vivo recoveries of both probes, determined by using naproxen as retrodialysis calibrator, were 26.0 +/- 0.3 and 72.9 +/- 0.7% for dermal and subcutaneous probe, respectively.",Study of the percutaneous penetration of flurbiprofen by cutaneous and subcutaneous microdialysis after iontophoretic delivery in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761938/),%,72.9,142392,DB00788,Naproxen
,15761938,C(max),"After iontophoretic delivery, a gradient in mean tissue unbound concentrations was observed, with a C(max) in dermis of 8.7 +/- 0.4 microg/mL as compared with subcutaneous C(max) of 0.5 +/- 0.1 microg/mL.",Study of the percutaneous penetration of flurbiprofen by cutaneous and subcutaneous microdialysis after iontophoretic delivery in rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761938/),[μg] / [ml],8.7,142393,DB00788,Naproxen
,15761938,C(max),"After iontophoretic delivery, a gradient in mean tissue unbound concentrations was observed, with a C(max) in dermis of 8.7 +/- 0.4 microg/mL as compared with subcutaneous C(max) of 0.5 +/- 0.1 microg/mL.",Study of the percutaneous penetration of flurbiprofen by cutaneous and subcutaneous microdialysis after iontophoretic delivery in rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761938/),[μg] / [ml],0.5,142394,DB00788,Naproxen
,15761938,T(max),Total plasma concentration curves showed a rapid absorption phase with a T(max) of 30 min and C(max) of 1.8 +/- 0.1 microg/mL.,Study of the percutaneous penetration of flurbiprofen by cutaneous and subcutaneous microdialysis after iontophoretic delivery in rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761938/),min,30,142395,DB00788,Naproxen
,15761938,C(max),Total plasma concentration curves showed a rapid absorption phase with a T(max) of 30 min and C(max) of 1.8 +/- 0.1 microg/mL.,Study of the percutaneous penetration of flurbiprofen by cutaneous and subcutaneous microdialysis after iontophoretic delivery in rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761938/),[μg] / [ml],1.8,142396,DB00788,Naproxen
,7952121,run time,Detection was at 325 nm and run time was 10 min.,Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952121/),min,10,142547,DB00788,Naproxen
,7952121,Retention times,"Retention times of R- and S-ketorolac and of S(+)-naproxen were 3.3, 4.8 and 6.4 min, respectively.",Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952121/),min,3.3,142548,DB00788,Naproxen
,7952121,Retention times,"Retention times of R- and S-ketorolac and of S(+)-naproxen were 3.3, 4.8 and 6.4 min, respectively.",Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952121/),min,4.8,142549,DB00788,Naproxen
,7952121,Retention times,"Retention times of R- and S-ketorolac and of S(+)-naproxen were 3.3, 4.8 and 6.4 min, respectively.",Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952121/),min,6.4,142550,DB00788,Naproxen
,7952121,retention time,The metabolite p-hydroxyketorolac was not resolved enantiomerically and had a retention time of 2.2 min.,Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952121/),min,2.2,142551,DB00788,Naproxen
,6581529,steady state concentration,"The mean steady state concentration and the mean half-life, calculated from the 12-hourly dosage schedule, were 45.0 +/- 1.7 mg/l and 15.2 +/- 1.4 hours, respectively.",Bioavailability of naproxen tablets and suppositories in steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6581529/),[mg] / [l],45.0,143507,DB00788,Naproxen
,6581529,half-life,"The mean steady state concentration and the mean half-life, calculated from the 12-hourly dosage schedule, were 45.0 +/- 1.7 mg/l and 15.2 +/- 1.4 hours, respectively.",Bioavailability of naproxen tablets and suppositories in steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6581529/),h,15.2,143508,DB00788,Naproxen
,6581529,relative bioavailability,"Average serum profiles for tablets and suppositories were very similar and gave a relative bioavailability of suppositories compared to tablets of 103% +/- 4%, suggesting comparable efficacy of the two administration forms.",Bioavailability of naproxen tablets and suppositories in steady state. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6581529/),%,103,143509,DB00788,Naproxen
,15193725,R,"The calculated electrophoretic parameters of the analytes were as follows: electrophoretic mobility, micorep(-)-R = -0.75 x 10(-4) to -0.30 x 10(-4) cm2/Vs; micorep(+)-S = -0.83 -(-0.38) cm2/Vs and electroosmotic mobility, microEOF = 2.35 x 10(-4) cm2/Vs, migration times, tmigr R = 12.55 - 16.07 min; tmigr s = 13.08 - 16.9 min, resolution factors, RS = 1.88 - 3.70 and chiral selectivity, alpha = 1.16 - 1.34.",High performance capillary electrophoresis for determination of the enantiomers of 2-arylpropionic acid derivatives in human serum. Pharmacokinetic studies of ketoprofen enantiomers following administration of standard and sustained release tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15193725/),min,12.55 - 16.07,145171,DB00788,Naproxen
,15193725,tmigr s,"The calculated electrophoretic parameters of the analytes were as follows: electrophoretic mobility, micorep(-)-R = -0.75 x 10(-4) to -0.30 x 10(-4) cm2/Vs; micorep(+)-S = -0.83 -(-0.38) cm2/Vs and electroosmotic mobility, microEOF = 2.35 x 10(-4) cm2/Vs, migration times, tmigr R = 12.55 - 16.07 min; tmigr s = 13.08 - 16.9 min, resolution factors, RS = 1.88 - 3.70 and chiral selectivity, alpha = 1.16 - 1.34.",High performance capillary electrophoresis for determination of the enantiomers of 2-arylpropionic acid derivatives in human serum. Pharmacokinetic studies of ketoprofen enantiomers following administration of standard and sustained release tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15193725/),min,13.08 - 16.9,145172,DB00788,Naproxen
,15193725,Recovery,Recovery of the enantiomers from serum was about 90%.,High performance capillary electrophoresis for determination of the enantiomers of 2-arylpropionic acid derivatives in human serum. Pharmacokinetic studies of ketoprofen enantiomers following administration of standard and sustained release tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15193725/),%,90,145173,DB00788,Naproxen
,16112626,flow rate,"Chromatographic separation was performed on a Zorbax SB-C(18) Column (100 mmx3.0mm i.d. with 3.5 microm particle size) with the mobile phase consisting of acetonitrile and 0.1% acetic acid (pH 4, adjusted with ammonia solution) (65:35, v/v), and the flow rate was set at 0.3 ml/min.",Quantification of lipoic acid in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16112626/),[ml] / [min],0.3,146775,DB00788,Naproxen
,8024123,absolute recovery,"The efficiency of the extraction procedure expressed by the absolute recovery was 94.6 +/- 0.7% (mean +/- s) for the concentration range tested, and the limit of quantification attained according to the IUPAC definition was 2.42 mg l-1.",Second-derivative spectrophotometric determination of naproxen in the presence of its metabolite in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8024123/),%,94.6,147408,DB00788,Naproxen
,8835565,concentrations required for 50% inhibition (EC50),Data from the single dose study revealed that the mean (+/- SD) of the concentrations required for 50% inhibition (EC50) of platelet derived TXB2 by total naproxen was 7.7 +/- 4.4 micrograms/ml (n = 5) and for unbound drug 25.4 +/- 22.0 ng/ml (n = 5).,Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835565/),[μg] / [ml],7.7,154890,DB00788,Naproxen
,8835565,unbound drug,Data from the single dose study revealed that the mean (+/- SD) of the concentrations required for 50% inhibition (EC50) of platelet derived TXB2 by total naproxen was 7.7 +/- 4.4 micrograms/ml (n = 5) and for unbound drug 25.4 +/- 22.0 ng/ml (n = 5).,Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835565/),[ng] / [ml],25.4,154891,DB00788,Naproxen
,6698666,Tmax,"Tmax (1.4 h) was significantly shorter after the administration of naproxen sodium suppositories than after naproxen tablets (2.4 h), whereas Cmax was higher after the tablet formulation.",Bioavailability of naproxen sodium suppositories. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698666/),h,1.4,155707,DB00788,Naproxen
,6698666,Tmax,"Tmax (1.4 h) was significantly shorter after the administration of naproxen sodium suppositories than after naproxen tablets (2.4 h), whereas Cmax was higher after the tablet formulation.",Bioavailability of naproxen sodium suppositories. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698666/),h,2.4,155708,DB00788,Naproxen
,21628602,t(max),"Naproxen plasma profiles were similar between the NAP/ESO tablet and EC naproxen, although median t(max) was longest for the NAP/ESO tablet (5.3 vs 3.5-4.0 hours).",Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628602/),h,5.3,160356,DB00788,Naproxen
,21628602,t(max),"Naproxen plasma profiles were similar between the NAP/ESO tablet and EC naproxen, although median t(max) was longest for the NAP/ESO tablet (5.3 vs 3.5-4.0 hours).",Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628602/),h,3.5-4.0,160357,DB00788,Naproxen
,21628602,t(max),The NAP/ESO tablet produced much shorter esomeprazole t(max) than the EC esomeprazole formulation (0.45 vs 2.5 hours).,Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628602/),h,0.45,160358,DB00788,Naproxen
,21628602,t(max),The NAP/ESO tablet produced much shorter esomeprazole t(max) than the EC esomeprazole formulation (0.45 vs 2.5 hours).,Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628602/),h,2.5,160359,DB00788,Naproxen
,9342419,Retention times,"Retention times for diclofenac and the internal standard (naproxen) were 3.5 and 6 min, respectively.",Determination of diclofenac in micro-whole blood samples by high-performance liquid chromatography with electrochemical detection. Application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342419/),min,3.5,169052,DB00788,Naproxen
,9342419,Retention times,"Retention times for diclofenac and the internal standard (naproxen) were 3.5 and 6 min, respectively.",Determination of diclofenac in micro-whole blood samples by high-performance liquid chromatography with electrochemical detection. Application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342419/),min,6,169053,DB00788,Naproxen
,9342419,detection limit,"The method was linear in the range of 25 to 2000 ng/ml and the detection limit of the method was 10 ng/ml, using 100 microliters of whole blood sample.",Determination of diclofenac in micro-whole blood samples by high-performance liquid chromatography with electrochemical detection. Application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342419/),[ng] / [ml],10,169054,DB00788,Naproxen
,9342419,half-life,Then concentration decayed with a half-life of about 15 h.,Determination of diclofenac in micro-whole blood samples by high-performance liquid chromatography with electrochemical detection. Application in a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342419/),h,15,169055,DB00788,Naproxen
,1297641,plasma AUC,It was found that average plasma AUC values were 1978.7 mcg.hr/ml in fasting participants and 1778.6 mcg.hr/ml in postprandial participants.,Bioavailability of a new controlled-release oral naproxen formulation given with and without food. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1297641/),[h·mcg] / [ml],1978.7,173297,DB00788,Naproxen
,1297641,plasma AUC,It was found that average plasma AUC values were 1978.7 mcg.hr/ml in fasting participants and 1778.6 mcg.hr/ml in postprandial participants.,Bioavailability of a new controlled-release oral naproxen formulation given with and without food. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1297641/),[h·mcg] / [ml],1778.6,173298,DB00788,Naproxen
,9777110,faecal blood loss,"Mean 24 hour faecal blood loss with diclofenac (0.53 mL +/- 0.21) was not significantly different from control (0.28 mL +/- 0.06), whereas it was significantly increased with naproxen (2.76 mL +/- 2.22) and piroxicam (1.16 mL +/- 0.62), p = 0.0013.",NSAIDs and faecal blood loss in elderly patients with osteoarthritis: is plasma half-life relevant? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9777110/),ml,0.53,175748,DB00788,Naproxen
,9777110,faecal blood loss,"Mean 24 hour faecal blood loss with diclofenac (0.53 mL +/- 0.21) was not significantly different from control (0.28 mL +/- 0.06), whereas it was significantly increased with naproxen (2.76 mL +/- 2.22) and piroxicam (1.16 mL +/- 0.62), p = 0.0013.",NSAIDs and faecal blood loss in elderly patients with osteoarthritis: is plasma half-life relevant? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9777110/),ml,0.28,175749,DB00788,Naproxen
,9777110,faecal blood loss,"Mean 24 hour faecal blood loss with diclofenac (0.53 mL +/- 0.21) was not significantly different from control (0.28 mL +/- 0.06), whereas it was significantly increased with naproxen (2.76 mL +/- 2.22) and piroxicam (1.16 mL +/- 0.62), p = 0.0013.",NSAIDs and faecal blood loss in elderly patients with osteoarthritis: is plasma half-life relevant? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9777110/),ml,2.76,175750,DB00788,Naproxen
,9777110,faecal blood loss,"Mean 24 hour faecal blood loss with diclofenac (0.53 mL +/- 0.21) was not significantly different from control (0.28 mL +/- 0.06), whereas it was significantly increased with naproxen (2.76 mL +/- 2.22) and piroxicam (1.16 mL +/- 0.62), p = 0.0013.",NSAIDs and faecal blood loss in elderly patients with osteoarthritis: is plasma half-life relevant? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9777110/),ml,1.16,175751,DB00788,Naproxen
,6487459,Total plasma clearance/bioavailability (CL/F),"Total plasma clearance/bioavailability (CL/F) of naproxen after a single 375 mg oral dose was found to be less in a group of 10 healthy men between 66 and 81 years of age than in 10 healthy men between 22 and 39 years (0.318 +/- 0.078, 0.416 +/- 0.061 l/h).",Naproxen pharmacokinetics in the elderly. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487459/),[l] / [h],0.318,176819,DB00788,Naproxen
,6487459,Total plasma clearance/bioavailability (CL/F),"Total plasma clearance/bioavailability (CL/F) of naproxen after a single 375 mg oral dose was found to be less in a group of 10 healthy men between 66 and 81 years of age than in 10 healthy men between 22 and 39 years (0.318 +/- 0.078, 0.416 +/- 0.061 l/h).",Naproxen pharmacokinetics in the elderly. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487459/),[l] / [h],0.416,176820,DB00788,Naproxen
,6487459,unbound clearance/bioavailability,"The lowered protein binding tended to obscure a 50% decrement in the intrinsic clearance of naproxen in the elderly as estimated by unbound clearance/bioavailability (213 +/- 64, 396 +/- 155 l/h).",Naproxen pharmacokinetics in the elderly. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487459/),[l] / [h],213,176821,DB00788,Naproxen
,6487459,unbound clearance/bioavailability,"The lowered protein binding tended to obscure a 50% decrement in the intrinsic clearance of naproxen in the elderly as estimated by unbound clearance/bioavailability (213 +/- 64, 396 +/- 155 l/h).",Naproxen pharmacokinetics in the elderly. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487459/),[l] / [h],396,176822,DB00788,Naproxen
,6487459,steady-state plasma concentrations,"As a result, mean steady-state plasma concentrations of naproxen were indistinguishable between the elderly and young (64.2 +/- 8.5, 58.2 +/- 8.1 mg/l) but the elderly generated twice the mean steady-state unbound plasma drug concentration (0.157 +/- 0.039, 0.0859 +/- 0.0212 mg/l).",Naproxen pharmacokinetics in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487459/),[mg] / [l],64.2,176823,DB00788,Naproxen
,6487459,steady-state plasma concentrations,"As a result, mean steady-state plasma concentrations of naproxen were indistinguishable between the elderly and young (64.2 +/- 8.5, 58.2 +/- 8.1 mg/l) but the elderly generated twice the mean steady-state unbound plasma drug concentration (0.157 +/- 0.039, 0.0859 +/- 0.0212 mg/l).",Naproxen pharmacokinetics in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487459/),[mg] / [l],58.2,176824,DB00788,Naproxen
,6487459,steady-state unbound plasma drug concentration,"As a result, mean steady-state plasma concentrations of naproxen were indistinguishable between the elderly and young (64.2 +/- 8.5, 58.2 +/- 8.1 mg/l) but the elderly generated twice the mean steady-state unbound plasma drug concentration (0.157 +/- 0.039, 0.0859 +/- 0.0212 mg/l).",Naproxen pharmacokinetics in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487459/),[mg] / [l],0.157,176825,DB00788,Naproxen
,6487459,steady-state unbound plasma drug concentration,"As a result, mean steady-state plasma concentrations of naproxen were indistinguishable between the elderly and young (64.2 +/- 8.5, 58.2 +/- 8.1 mg/l) but the elderly generated twice the mean steady-state unbound plasma drug concentration (0.157 +/- 0.039, 0.0859 +/- 0.0212 mg/l).",Naproxen pharmacokinetics in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487459/),[mg] / [l],0.0859,176826,DB00788,Naproxen
,19679500,IC(50),"IC(50) values for PGE(2) inhibition showed a shift from 2840+/-510 to 4000+/-677ng/ml(mean+/-SD), whilst IC(50) values for TXB(2) inhibition increased from 1180+/-323 to 3360+/-453ng/ml in healthy and FCA-inoculated animals, respectively.",Impact of chronic inflammation on the pharmacokinetic-pharmacodynamic relationship of naproxen. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679500/),[ng] / [ml],2840,181391,DB00788,Naproxen
,19679500,IC(50),"IC(50) values for PGE(2) inhibition showed a shift from 2840+/-510 to 4000+/-677ng/ml(mean+/-SD), whilst IC(50) values for TXB(2) inhibition increased from 1180+/-323 to 3360+/-453ng/ml in healthy and FCA-inoculated animals, respectively.",Impact of chronic inflammation on the pharmacokinetic-pharmacodynamic relationship of naproxen. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679500/),[ng] / [ml],4000,181392,DB00788,Naproxen
,19679500,IC(50),"IC(50) values for PGE(2) inhibition showed a shift from 2840+/-510 to 4000+/-677ng/ml(mean+/-SD), whilst IC(50) values for TXB(2) inhibition increased from 1180+/-323 to 3360+/-453ng/ml in healthy and FCA-inoculated animals, respectively.",Impact of chronic inflammation on the pharmacokinetic-pharmacodynamic relationship of naproxen. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679500/),[ng] / [ml],1180,181393,DB00788,Naproxen
,19679500,IC(50),"IC(50) values for PGE(2) inhibition showed a shift from 2840+/-510 to 4000+/-677ng/ml(mean+/-SD), whilst IC(50) values for TXB(2) inhibition increased from 1180+/-323 to 3360+/-453ng/ml in healthy and FCA-inoculated animals, respectively.",Impact of chronic inflammation on the pharmacokinetic-pharmacodynamic relationship of naproxen. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679500/),[ng] / [ml],3360,181394,DB00788,Naproxen
,3828195,area under the serum concentration-time curve,"The area under the serum concentration-time curve of total naproxen during a dose interval, AUC (0,12), smaller in patients (641 +/- 101 mg l-1 h) than in volunteers (896 +/- 85 mg l-1 h; P less than 0.0001).",Naproxen pharmacokinetics in patients with rheumatoid arthritis during active polyarticular inflammation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828195/),[h·mg] / [l],641,181683,DB00788,Naproxen
,3828195,area under the serum concentration-time curve,"The area under the serum concentration-time curve of total naproxen during a dose interval, AUC (0,12), smaller in patients (641 +/- 101 mg l-1 h) than in volunteers (896 +/- 85 mg l-1 h; P less than 0.0001).",Naproxen pharmacokinetics in patients with rheumatoid arthritis during active polyarticular inflammation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828195/),[h·mg] / [l],896,181684,DB00788,Naproxen
,3828195,"AUCu (0,12)","The unbound naproxen AUCu (0,12) was larger in patients (1.9 +/- 0.9 mg l-1 h) than in volunteers (0.7 +/- 0.2 mg l-1 h; P less than 0.01).",Naproxen pharmacokinetics in patients with rheumatoid arthritis during active polyarticular inflammation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828195/),[h·mg] / [l],1.9,181685,DB00788,Naproxen
,3828195,"AUCu (0,12)","The unbound naproxen AUCu (0,12) was larger in patients (1.9 +/- 0.9 mg l-1 h) than in volunteers (0.7 +/- 0.2 mg l-1 h; P less than 0.01).",Naproxen pharmacokinetics in patients with rheumatoid arthritis during active polyarticular inflammation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828195/),[h·mg] / [l],0.7,181686,DB00788,Naproxen
,8011964,time Tmax to reach peak concentration,"The median time Tmax to reach peak concentration for product A was shorter than that for product B (1.025 h versus 1.5 h) but A and B were similar with respect to median peak plasma concentration Cmax (77.9 mg l-1 versus 71.4 mg l-1), and average area AUC0-infinity under the plasma concentration-time curve (1210.2 mg l-1 h versus 1211.0 mg l-1 h).",Comparative in vitro and in vivo bioavailability of naproxen from tablet and caplet formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011964/),h,1.025,184028,DB00788,Naproxen
,8011964,time Tmax to reach peak concentration,"The median time Tmax to reach peak concentration for product A was shorter than that for product B (1.025 h versus 1.5 h) but A and B were similar with respect to median peak plasma concentration Cmax (77.9 mg l-1 versus 71.4 mg l-1), and average area AUC0-infinity under the plasma concentration-time curve (1210.2 mg l-1 h versus 1211.0 mg l-1 h).",Comparative in vitro and in vivo bioavailability of naproxen from tablet and caplet formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011964/),h,1.5,184029,DB00788,Naproxen
,8011964,peak plasma concentration Cmax,"The median time Tmax to reach peak concentration for product A was shorter than that for product B (1.025 h versus 1.5 h) but A and B were similar with respect to median peak plasma concentration Cmax (77.9 mg l-1 versus 71.4 mg l-1), and average area AUC0-infinity under the plasma concentration-time curve (1210.2 mg l-1 h versus 1211.0 mg l-1 h).",Comparative in vitro and in vivo bioavailability of naproxen from tablet and caplet formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011964/),[mg] / [l],77.9,184030,DB00788,Naproxen
,8011964,peak plasma concentration Cmax,"The median time Tmax to reach peak concentration for product A was shorter than that for product B (1.025 h versus 1.5 h) but A and B were similar with respect to median peak plasma concentration Cmax (77.9 mg l-1 versus 71.4 mg l-1), and average area AUC0-infinity under the plasma concentration-time curve (1210.2 mg l-1 h versus 1211.0 mg l-1 h).",Comparative in vitro and in vivo bioavailability of naproxen from tablet and caplet formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011964/),[mg] / [l],71.4,184031,DB00788,Naproxen
,8011964,area AUC0-infinity under the plasma concentration-time curve,"The median time Tmax to reach peak concentration for product A was shorter than that for product B (1.025 h versus 1.5 h) but A and B were similar with respect to median peak plasma concentration Cmax (77.9 mg l-1 versus 71.4 mg l-1), and average area AUC0-infinity under the plasma concentration-time curve (1210.2 mg l-1 h versus 1211.0 mg l-1 h).",Comparative in vitro and in vivo bioavailability of naproxen from tablet and caplet formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011964/),[h·mg] / [l],1210.2,184032,DB00788,Naproxen
,8011964,area AUC0-infinity under the plasma concentration-time curve,"The median time Tmax to reach peak concentration for product A was shorter than that for product B (1.025 h versus 1.5 h) but A and B were similar with respect to median peak plasma concentration Cmax (77.9 mg l-1 versus 71.4 mg l-1), and average area AUC0-infinity under the plasma concentration-time curve (1210.2 mg l-1 h versus 1211.0 mg l-1 h).",Comparative in vitro and in vivo bioavailability of naproxen from tablet and caplet formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011964/),[h·mg] / [l],1211.0,184033,DB00788,Naproxen
,8011964,mean dissolution time MDT,"In vitro parameters (A versus B) of mean dissolution time MDT (5.03 min versus 15.0 min), and time for 70% dissolution T70 (6.67 min versus 20.2 min), differed significantly.",Comparative in vitro and in vivo bioavailability of naproxen from tablet and caplet formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011964/),min,5.03,184034,DB00788,Naproxen
,8011964,mean dissolution time MDT,"In vitro parameters (A versus B) of mean dissolution time MDT (5.03 min versus 15.0 min), and time for 70% dissolution T70 (6.67 min versus 20.2 min), differed significantly.",Comparative in vitro and in vivo bioavailability of naproxen from tablet and caplet formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011964/),min,15.0,184035,DB00788,Naproxen
,8011964,time for 70% dissolution T70,"In vitro parameters (A versus B) of mean dissolution time MDT (5.03 min versus 15.0 min), and time for 70% dissolution T70 (6.67 min versus 20.2 min), differed significantly.",Comparative in vitro and in vivo bioavailability of naproxen from tablet and caplet formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011964/),min,6.67,184036,DB00788,Naproxen
,8011964,time for 70% dissolution T70,"In vitro parameters (A versus B) of mean dissolution time MDT (5.03 min versus 15.0 min), and time for 70% dissolution T70 (6.67 min versus 20.2 min), differed significantly.",Comparative in vitro and in vivo bioavailability of naproxen from tablet and caplet formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011964/),min,20.2,184037,DB00788,Naproxen
,1796038,Clp,"Similar plasma kinetics and organ distribution for native lysozyme and the drug conjugate were observed (Clp = 1.2 and 1.1 ml/min; t1/2,beta = 85 and 75 min, respectively).",Low molecular weight proteins as carriers for renal drug targeting: naproxen-lysozyme. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796038/),[ml] / [min],1.2,186007,DB00788,Naproxen
,1796038,Clp,"Similar plasma kinetics and organ distribution for native lysozyme and the drug conjugate were observed (Clp = 1.2 and 1.1 ml/min; t1/2,beta = 85 and 75 min, respectively).",Low molecular weight proteins as carriers for renal drug targeting: naproxen-lysozyme. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796038/),[ml] / [min],1.1,186008,DB00788,Naproxen
,1796038,"t1/2,beta","Similar plasma kinetics and organ distribution for native lysozyme and the drug conjugate were observed (Clp = 1.2 and 1.1 ml/min; t1/2,beta = 85 and 75 min, respectively).",Low molecular weight proteins as carriers for renal drug targeting: naproxen-lysozyme. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796038/),min,85,186009,DB00788,Naproxen
,1796038,"t1/2,beta","Similar plasma kinetics and organ distribution for native lysozyme and the drug conjugate were observed (Clp = 1.2 and 1.1 ml/min; t1/2,beta = 85 and 75 min, respectively).",Low molecular weight proteins as carriers for renal drug targeting: naproxen-lysozyme. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796038/),min,75,186010,DB00788,Naproxen
,1796038,t1/2,"In case of the uncoupled naproxen-lysozyme mixture, a monoexponential plasma disappearance of naproxen with a t1/2 of 2.8 hr was observed, coinciding with urinary excretion of naproxen metabolites (mainly 6-desmethylnaproxen sulfate; 6-DMN-S) between 2 and 8 hr after injection.",Low molecular weight proteins as carriers for renal drug targeting: naproxen-lysozyme. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796038/),h,2.8,186011,DB00788,Naproxen
,1796038,Urinary recovery,Urinary recovery of total metabolites was 59% of the naproxen dose.,Low molecular weight proteins as carriers for renal drug targeting: naproxen-lysozyme. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796038/),%,59,186012,DB00788,Naproxen
,7612058,peak plasma levels,In control animals naproxen peak plasma levels of 35 +/- 0.4 micrograms.,Relationship between naproxen plasma concentration and its anti-inflammatory effect in experimental hepatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612058/),μg,35,190139,DB00788,Naproxen
,7612058,half-life,"Concentration then decayed, half-life being 5.2 +/- 0.4 h.",Relationship between naproxen plasma concentration and its anti-inflammatory effect in experimental hepatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612058/),h,5.2,190140,DB00788,Naproxen
,7612058,AUC,AUC was 131 +/- 5 micrograms.h.ml-1.,Relationship between naproxen plasma concentration and its anti-inflammatory effect in experimental hepatitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612058/),[h·μg] / [ml],131,190141,DB00788,Naproxen
,7612058,peak plasma levels,In intoxicated rats peak plasma levels of 29 +/- 0.3 micrograms.,Relationship between naproxen plasma concentration and its anti-inflammatory effect in experimental hepatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612058/),μg,29,190142,DB00788,Naproxen
,7612058,half-life,"ml-1 were reached in 0.7 +/- 0.1 h, half-life was increased to 11.1 +/- 1.3 h, and the AUC reached 259 +/- 21 micrograms.h.ml-1.",Relationship between naproxen plasma concentration and its anti-inflammatory effect in experimental hepatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612058/),h,11.1,190143,DB00788,Naproxen
,7612058,AUC,"ml-1 were reached in 0.7 +/- 0.1 h, half-life was increased to 11.1 +/- 1.3 h, and the AUC reached 259 +/- 21 micrograms.h.ml-1.",Relationship between naproxen plasma concentration and its anti-inflammatory effect in experimental hepatitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612058/),[h·μg] / [ml],259,190144,DB00788,Naproxen
,23615159,baseline,Mean baseline (predose) BT for the 3 studies ranged from 4.72 to 6.13 minutes.,"The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23615159/),min,4.72 to 6.13,192647,DB00788,Naproxen
,23615159,BT,Mean baseline (predose) BT for the 3 studies ranged from 4.72 to 6.13 minutes.,"The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23615159/),min,4.72 to 6.13,192648,DB00788,Naproxen
,33176242,m,"The mass transition ion pairs were m/z 231.2 → 185.0, 346.9 → 198.2, 285.1 → 193.1 and 382.2 → 281.2 for NAP, ESOM, diazepam (IS for NAP) and celecoxib (IS for ESOM), respectively.",Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176242/),,231.2,193838,DB00788,Naproxen
,33176242,m,"The mass transition ion pairs were m/z 231.2 → 185.0, 346.9 → 198.2, 285.1 → 193.1 and 382.2 → 281.2 for NAP, ESOM, diazepam (IS for NAP) and celecoxib (IS for ESOM), respectively.",Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176242/),,346.9,193839,DB00788,Naproxen
,33176242,m,"The mass transition ion pairs were m/z 231.2 → 185.0, 346.9 → 198.2, 285.1 → 193.1 and 382.2 → 281.2 for NAP, ESOM, diazepam (IS for NAP) and celecoxib (IS for ESOM), respectively.",Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176242/),,285.1,193840,DB00788,Naproxen
,33176242,m,"The mass transition ion pairs were m/z 231.2 → 185.0, 346.9 → 198.2, 285.1 → 193.1 and 382.2 → 281.2 for NAP, ESOM, diazepam (IS for NAP) and celecoxib (IS for ESOM), respectively.",Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176242/),,382.2,193841,DB00788,Naproxen
,7450924,plasma half-life of the beta-phase,"In healthy volunteers, the plasma half-life of the beta-phase has an average value of 14.14 hrs while in patients it reaches a value of 20.36 hrs.",Naproxen disposition in hepatic and biliary disorders. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7450924/),h,14.14,195533,DB00788,Naproxen
,7450924,plasma half-life of the beta-phase,"In healthy volunteers, the plasma half-life of the beta-phase has an average value of 14.14 hrs while in patients it reaches a value of 20.36 hrs.",Naproxen disposition in hepatic and biliary disorders. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7450924/),h,20.36,195534,DB00788,Naproxen
,11304721,T(max),"Significant treatment differences seen for naproxen T(max) (0.3 h, males only) and diphenhydramine t(1/2,z) (0.8 h, females only) were minor and are unlikely to have therapeutic consequences.",Absence of pharmacokinetic interaction between orally co-administered naproxen sodium and diphenhydramine hydrochloride. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304721/),h,0.3,196206,DB00788,Naproxen
,11304721,"t(1/2,z)","Significant treatment differences seen for naproxen T(max) (0.3 h, males only) and diphenhydramine t(1/2,z) (0.8 h, females only) were minor and are unlikely to have therapeutic consequences.",Absence of pharmacokinetic interaction between orally co-administered naproxen sodium and diphenhydramine hydrochloride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304721/),h,0.8,196207,DB00788,Naproxen
,8668659,recoveries,"The in vitro recoveries of flurbiprofen and naproxen for these probes were 68.2 +/- 6.9% (mean +/- S.D., n = 12) and 66.5 +/- 7.3%, respectively.",Intravenous microdialysis in the mouse and the rat: development and pharmacokinetic application of a new probe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668659/),%,68.2,197363,DB00788,Naproxen
,8668659,recoveries,"The in vitro recoveries of flurbiprofen and naproxen for these probes were 68.2 +/- 6.9% (mean +/- S.D., n = 12) and 66.5 +/- 7.3%, respectively.",Intravenous microdialysis in the mouse and the rat: development and pharmacokinetic application of a new probe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668659/),%,66.5,197364,DB00788,Naproxen
,8668659,relatively loss,"The relatively loss by in vivo retrodialysis, measured the day after the implantation of the probes, was 66.1 +/- 8.8% for flurbiprofen and 60.9 +/- 9.9% for naproxen.",Intravenous microdialysis in the mouse and the rat: development and pharmacokinetic application of a new probe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668659/),%,66.1,197365,DB00788,Naproxen
,8668659,relatively loss,"The relatively loss by in vivo retrodialysis, measured the day after the implantation of the probes, was 66.1 +/- 8.8% for flurbiprofen and 60.9 +/- 9.9% for naproxen.",Intravenous microdialysis in the mouse and the rat: development and pharmacokinetic application of a new probe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668659/),%,60.9,197366,DB00788,Naproxen
,27020929,m/,"A triple-quadrupole mass spectrometer equipped with an electrospray source in the positive mode was set up in the selective reaction monitoring mode to detect the ion transitions m/z 231.67 → m/z 185.07, m/z 296.70 → m/z 157.30, m/z 354.80 → m/z 215.00, and m/z 336.80 → m/z 97.94 for naproxen, sumatriptan, aceclofenac, and naratriptan, respectively.",Development and validation of an LC-ESI-MS/MS method for the simultaneous quantification of naproxen and sumatriptan in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27020929/),,354.80,198149,DB00788,Naproxen
,9886235,volume of distribution during the terminal elimination phase (Vd(beta),"Thus, initial plasma concentrations of NAP HSA and naproxen were markedly lower in BDL rats accompanied by an increase of the volume of distribution during the terminal elimination phase (Vd(beta) BDL vs control 114 +/- 63 vs 50 +/- 7 and 202 +/- 24 vs 115 +/- 11 ml/kg for naproxen and NAP-HSA, respectively).",Effect of chronic bile duct obstruction and LPS upon targeting of naproxen to the liver using naproxen-albumin conjugate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9886235/),[ml] / [kg],114,201728,DB00788,Naproxen
,9886235,volume of distribution during the terminal elimination phase (Vd(beta),"Thus, initial plasma concentrations of NAP HSA and naproxen were markedly lower in BDL rats accompanied by an increase of the volume of distribution during the terminal elimination phase (Vd(beta) BDL vs control 114 +/- 63 vs 50 +/- 7 and 202 +/- 24 vs 115 +/- 11 ml/kg for naproxen and NAP-HSA, respectively).",Effect of chronic bile duct obstruction and LPS upon targeting of naproxen to the liver using naproxen-albumin conjugate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9886235/),[ml] / [kg],50,201729,DB00788,Naproxen
,9886235,volume of distribution during the terminal elimination phase (Vd(beta),"Thus, initial plasma concentrations of NAP HSA and naproxen were markedly lower in BDL rats accompanied by an increase of the volume of distribution during the terminal elimination phase (Vd(beta) BDL vs control 114 +/- 63 vs 50 +/- 7 and 202 +/- 24 vs 115 +/- 11 ml/kg for naproxen and NAP-HSA, respectively).",Effect of chronic bile duct obstruction and LPS upon targeting of naproxen to the liver using naproxen-albumin conjugate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9886235/),[ml] / [kg],202,201730,DB00788,Naproxen
,9886235,volume of distribution during the terminal elimination phase (Vd(beta),"Thus, initial plasma concentrations of NAP HSA and naproxen were markedly lower in BDL rats accompanied by an increase of the volume of distribution during the terminal elimination phase (Vd(beta) BDL vs control 114 +/- 63 vs 50 +/- 7 and 202 +/- 24 vs 115 +/- 11 ml/kg for naproxen and NAP-HSA, respectively).",Effect of chronic bile duct obstruction and LPS upon targeting of naproxen to the liver using naproxen-albumin conjugate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9886235/),[ml] / [kg],115,201731,DB00788,Naproxen
,9886235,terminal volume of distribution,"After injection of LPS, no significant change in the pharmacokinetics of NAP-HSA was found whereas the naproxen treated control animals showed an increase in the terminal volume of distribution (176 +/- 34 vs 115 +/- 11 ml/kg) as well as an elevation of the plasma half-life (171 +/- 27 vs 116 +/- 14 min).",Effect of chronic bile duct obstruction and LPS upon targeting of naproxen to the liver using naproxen-albumin conjugate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9886235/),[ml] / [kg],176,201732,DB00788,Naproxen
,9886235,terminal volume of distribution,"After injection of LPS, no significant change in the pharmacokinetics of NAP-HSA was found whereas the naproxen treated control animals showed an increase in the terminal volume of distribution (176 +/- 34 vs 115 +/- 11 ml/kg) as well as an elevation of the plasma half-life (171 +/- 27 vs 116 +/- 14 min).",Effect of chronic bile duct obstruction and LPS upon targeting of naproxen to the liver using naproxen-albumin conjugate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9886235/),[ml] / [kg],115,201733,DB00788,Naproxen
,9886235,plasma half-life,"After injection of LPS, no significant change in the pharmacokinetics of NAP-HSA was found whereas the naproxen treated control animals showed an increase in the terminal volume of distribution (176 +/- 34 vs 115 +/- 11 ml/kg) as well as an elevation of the plasma half-life (171 +/- 27 vs 116 +/- 14 min).",Effect of chronic bile duct obstruction and LPS upon targeting of naproxen to the liver using naproxen-albumin conjugate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9886235/),min,171,201734,DB00788,Naproxen
,9886235,plasma half-life,"After injection of LPS, no significant change in the pharmacokinetics of NAP-HSA was found whereas the naproxen treated control animals showed an increase in the terminal volume of distribution (176 +/- 34 vs 115 +/- 11 ml/kg) as well as an elevation of the plasma half-life (171 +/- 27 vs 116 +/- 14 min).",Effect of chronic bile duct obstruction and LPS upon targeting of naproxen to the liver using naproxen-albumin conjugate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9886235/),min,116,201735,DB00788,Naproxen
>,22818944,extraction recovery,Matrix effect was assessed by post-column analyte infusion and the extraction recovery was >95.0% across four quality control levels for both the analytes.,Challenges in the simultaneous quantitation of sumatriptan and naproxen in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22818944/),%,95.0,205117,DB00788,Naproxen
,17139160,flow-rate,A flow-rate of 0.5 ml/min was used at ambient temperature and sample detection was carried out at 254 nm.,Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),[ml] / [min],0.5,205472,DB00788,Naproxen
,17139160,time to reach the maximum,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),[μg] / [ml],11.7,205473,DB00788,Naproxen
,17139160,second peak,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),[μg] / [ml],4.5,205474,DB00788,Naproxen
,17139160,second peak,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),h,2.6,205475,DB00788,Naproxen
,17139160,second peak,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),h,9.0,205476,DB00788,Naproxen
,17139160,time to reach maximum,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),[μg] / [ml],10.5,205477,DB00788,Naproxen
,17139160,time to reach maximum,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),h,4.0,205478,DB00788,Naproxen
,8218967,t1/2,The mean t1/2 of naproxen in 9 subjects was 24.7 +/- 6.4 h (range 16 to 36 h).,"Pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218967/),h,24.7,207911,DB00788,Naproxen
,8218967,t1/2,"The t1/2 of 7.4 as found in subject number 10 must, therefore, be regarded as an extraordinary case (p < 0.0153).","Pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218967/),,7.4,207912,DB00788,Naproxen
,8218967,Binding to,"Binding to plasma proteins was measured as 98 per cent and 100 per cent, respectively for the unconjugated compounds naproxen and O-desmethylnaproxen.","Pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218967/),%,98,207913,DB00788,Naproxen
,8218967,Binding to,"Binding to plasma proteins was measured as 98 per cent and 100 per cent, respectively for the unconjugated compounds naproxen and O-desmethylnaproxen.","Pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218967/),%,100,207914,DB00788,Naproxen
,8218967,Binding,"Binding of the acyl glucuronides was less, being 92 per cent; for naproxen acyl glucuronide, 66 per cent for naproxen isoglucuronide, 72 per cent for O-desmethylnaproxen acyl glucuronide and 42 per cent for O-desmethylnaproxen isoglucuronide.","Pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218967/),%,92,207915,DB00788,Naproxen
,8218967,Binding,"Binding of the acyl glucuronides was less, being 92 per cent; for naproxen acyl glucuronide, 66 per cent for naproxen isoglucuronide, 72 per cent for O-desmethylnaproxen acyl glucuronide and 42 per cent for O-desmethylnaproxen isoglucuronide.","Pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218967/),%,66,207916,DB00788,Naproxen
,8218967,Binding,"Binding of the acyl glucuronides was less, being 92 per cent; for naproxen acyl glucuronide, 66 per cent for naproxen isoglucuronide, 72 per cent for O-desmethylnaproxen acyl glucuronide and 42 per cent for O-desmethylnaproxen isoglucuronide.","Pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218967/),%,72,207917,DB00788,Naproxen
,8218967,Binding,"Binding of the acyl glucuronides was less, being 92 per cent; for naproxen acyl glucuronide, 66 per cent for naproxen isoglucuronide, 72 per cent for O-desmethylnaproxen acyl glucuronide and 42 per cent for O-desmethylnaproxen isoglucuronide.","Pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218967/),%,42,207918,DB00788,Naproxen
,31194730,AUCo/AUCp plasma,"The model was also able to describe disease-mediated changes in neonates and young children (<3m postnatal age) related to meningitis and sepsis (range AUCo/AUCp plasma: 1.64-1.66, range AUCo/AUCp CSF: 1.43-1.73).",Development of a physiologically-based pharmacokinetic pediatric brain model for prediction of cerebrospinal fluid drug concentrations and the influence of meningitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194730/),,1.64-1.66,211062,DB00788,Naproxen
,31194730,AUCo/AUCp CSF,"The model was also able to describe disease-mediated changes in neonates and young children (<3m postnatal age) related to meningitis and sepsis (range AUCo/AUCp plasma: 1.64-1.66, range AUCo/AUCp CSF: 1.43-1.73).",Development of a physiologically-based pharmacokinetic pediatric brain model for prediction of cerebrospinal fluid drug concentrations and the influence of meningitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194730/),,1.43-1.73,211063,DB00788,Naproxen
>,12946535,extraction efficiency,The mean extraction efficiency was >95%.,Stereospecific high-performance liquid chromatographic analysis of flurbiprofen: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12946535/),%,95,212005,DB00788,Naproxen
,16682968,IC(80),"IC(80) estimates obtained in vitro were similar for PGE(2) inhibition (130.8 +/- 11 and 131.9 +/- 19 10(-6) M, mean +/- s.d. for humans and rats, respectively), but slightly different for TXB(2) inhibition (103.9+/-15 and 151.4 +/- 40 10(-6) M, mean +/- s.d. for humans and rats, respectively, P < 0.05).",Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16682968/),10,130.8,212177,DB00788,Naproxen
,16682968,IC(80),"IC(80) estimates obtained in vitro were similar for PGE(2) inhibition (130.8 +/- 11 and 131.9 +/- 19 10(-6) M, mean +/- s.d. for humans and rats, respectively), but slightly different for TXB(2) inhibition (103.9+/-15 and 151.4 +/- 40 10(-6) M, mean +/- s.d. for humans and rats, respectively, P < 0.05).",Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16682968/),M,131.9,212178,DB00788,Naproxen
,16682968,IC(80),"IC(80) estimates obtained in vitro were similar for PGE(2) inhibition (130.8 +/- 11 and 131.9 +/- 19 10(-6) M, mean +/- s.d. for humans and rats, respectively), but slightly different for TXB(2) inhibition (103.9+/-15 and 151.4 +/- 40 10(-6) M, mean +/- s.d. for humans and rats, respectively, P < 0.05).",Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16682968/),10,103.9,212179,DB00788,Naproxen
,16682968,IC(80),"IC(80) estimates obtained in vitro were similar for PGE(2) inhibition (130.8 +/- 11 and 131.9 +/- 19 10(-6) M, mean +/- s.d. for humans and rats, respectively), but slightly different for TXB(2) inhibition (103.9+/-15 and 151.4 +/- 40 10(-6) M, mean +/- s.d. for humans and rats, respectively, P < 0.05).",Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16682968/),M,151.4,212180,DB00788,Naproxen
,8292066,relative rectal bioavailability,The relative rectal bioavailability of naproxen from the compressed suppositories was 96.7 +/- 2.6%.,Comparative pharmacokinetic evaluation of compressed naproxen suppositories in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8292066/),%,96.7,215248,DB00788,Naproxen
,1686227,inversion ratio,The (R)- to (S)-enantiomer inversion ratio for flunoxaprofen in rats was 0.54.,"Stereoselective disposition of carprofen, flunoxaprofen, and naproxen in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686227/),,0.54,217457,DB00788,Naproxen
,25550191,run time,Separation was performed on a Synergi Fusion-RP C18 column with a run time of 4 min.,Simultaneous quantification of naproxcinod and its active metabolite naproxen in rat plasma using LC-MS/MS: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25550191/),min,4,218894,DB00788,Naproxen
more,25550191,extraction recovery,The mean extraction recovery of all analytes was more than 93.1% efficient.,Simultaneous quantification of naproxcinod and its active metabolite naproxen in rat plasma using LC-MS/MS: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25550191/),%·efficient,93.1,218895,DB00788,Naproxen
,6704505,maximum amount,The maximum amount of naproxen adsorbed by the resin is close to 2.2 mM g-1.,Interaction of naproxen with cholestyramine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6704505/),[mM] / [g],2.2,220646,DB00788,Naproxen
,1716910,absorption fractions,"Compared to the administration of an oral solution of an equivalent dose of parent ketoprofen, the average absorption fractions for the different prodrugs ranged from 100 to 67%.",Bioavailability of ketoprofen from orally administered ketoprofen-dextran ester prodrugs in the pig. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1716910/),%,100 to 67,221871,DB00788,Naproxen
,1716910,lag time,The ketoprofen plasma profiles for all the administered prodrugs exhibited a characteristic lag time of ketoprofen appearance in the blood (2-3 h).,Bioavailability of ketoprofen from orally administered ketoprofen-dextran ester prodrugs in the pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1716910/),h,2-3,221872,DB00788,Naproxen
,27803469,flow rate,Chromatographic separation was performed using Kinetex® C8 column with an isocratic mobile phase consisting of acetonitrile and 10-mM potassium phosphate buffer (pH 6.0) at a flow rate of 1.0 mL/min.,Development of HPLC Method for the Determination of Buspirone in Rat Plasma Using Fluorescence Detection and Its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27803469/),[ml] / [min],1.0,222616,DB00788,Naproxen
,27803469,limit of detection,"The linearity was established at 20.0-5000 ng/mL, and the limit of detection was 6.51 ng/mL.",Development of HPLC Method for the Determination of Buspirone in Rat Plasma Using Fluorescence Detection and Its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27803469/),[ng] / [ml],6.51,222617,DB00788,Naproxen
,17470643,K(i),ELN441958 competitively inhibited the binding of the B(1) agonist ligand [(3)H]desArg(10)-kallidin ([(3)H]DAKD) to IMR-90 human fibroblast membranes with high affinity (K(i) = 0.26 +/- 0.02 nM).,"Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17470643/),nM,0.26,223016,DB00788,Naproxen
,17470643,ED(50),"ELN441958 dose-dependently reduced carrageenan-induced thermal hyperalgesia in a rhesus monkey tail-withdrawal model, with an ED(50) approximately 3 mg/kg s.c.","Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17470643/),[mg] / [kg],3,223017,DB00788,Naproxen
,6663474,area under the plasma concentration-time curves (AUC,There was a disproportionate increase in the area under the plasma concentration-time curves (AUC 750 mg/AUC 250 mg was 3.84 for subject A and 4.22 for subject B) and a reduction in plasma clearance after the 750-mg dose of diflunisal.,High-performance liquid chromatographic analysis of diflunisal in plasma and urine: application to pharmacokinetic studies in two normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6663474/),,3.84,227186,DB00788,Naproxen
,6663474,area under the plasma concentration-time curves (AUC,There was a disproportionate increase in the area under the plasma concentration-time curves (AUC 750 mg/AUC 250 mg was 3.84 for subject A and 4.22 for subject B) and a reduction in plasma clearance after the 750-mg dose of diflunisal.,High-performance liquid chromatographic analysis of diflunisal in plasma and urine: application to pharmacokinetic studies in two normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6663474/),,4.22,227187,DB00788,Naproxen
,24697979,anti-Xa activity,"Mean (standard deviation [SD]) anti-Xa activity at 3 h post-dose was approximately 60% higher following co-administration compared with apixaban alone, 4.4 [1.0] vs. 2.7 [0.7] IU ml(-1) , consistent with the apixaban concentration increase following co-administration.",Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697979/),[iu] / [ml],4.4,236981,DB00788,Naproxen
,24697979,anti-Xa activity,"Mean (standard deviation [SD]) anti-Xa activity at 3 h post-dose was approximately 60% higher following co-administration compared with apixaban alone, 4.4 [1.0] vs. 2.7 [0.7] IU ml(-1) , consistent with the apixaban concentration increase following co-administration.",Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697979/),[iu] / [ml],2.7,236982,DB00788,Naproxen
,24697979,bleeding time,"Mean [SD] bleeding time was higher following co-administration (9.1 [4.1] min) compared with either agent alone (5.8 [2.3] and 6.9 [2.6] min for apixaban and naproxen, respectively).",Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697979/),min,9.1,236983,DB00788,Naproxen
,24697979,bleeding time,"Mean [SD] bleeding time was higher following co-administration (9.1 [4.1] min) compared with either agent alone (5.8 [2.3] and 6.9 [2.6] min for apixaban and naproxen, respectively).",Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697979/),min,5.8,236984,DB00788,Naproxen
,24697979,bleeding time,"Mean [SD] bleeding time was higher following co-administration (9.1 [4.1] min) compared with either agent alone (5.8 [2.3] and 6.9 [2.6] min for apixaban and naproxen, respectively).",Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697979/),min,6.9,236985,DB00788,Naproxen
>,15901348,volume of distribution (Vss,"AZD3582 had intermediate and passive intestinal permeability (40 times lower than for naproxen), high systemic plasma clearance (CL), substantial gastrointestinal hydrolysis, intermediate volume of distribution (Vss; >or=3.4 L kg-1) and half-life (t1/2; 7 h), negligible plasma protein binding (approximately 0.1%), low/intermediate oral uptake (>or=13% as intact substance) and low and varying oral bioavailability (mean 1.4% in minipigs and 3.9% in dogs).",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),[l] / [kg],3.4,240319,DB00788,Naproxen
,15901348,half-life (t1/2,"AZD3582 had intermediate and passive intestinal permeability (40 times lower than for naproxen), high systemic plasma clearance (CL), substantial gastrointestinal hydrolysis, intermediate volume of distribution (Vss; >or=3.4 L kg-1) and half-life (t1/2; 7 h), negligible plasma protein binding (approximately 0.1%), low/intermediate oral uptake (>or=13% as intact substance) and low and varying oral bioavailability (mean 1.4% in minipigs and 3.9% in dogs).",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),h,7,240320,DB00788,Naproxen
,15901348,plasma protein binding,"AZD3582 had intermediate and passive intestinal permeability (40 times lower than for naproxen), high systemic plasma clearance (CL), substantial gastrointestinal hydrolysis, intermediate volume of distribution (Vss; >or=3.4 L kg-1) and half-life (t1/2; 7 h), negligible plasma protein binding (approximately 0.1%), low/intermediate oral uptake (>or=13% as intact substance) and low and varying oral bioavailability (mean 1.4% in minipigs and 3.9% in dogs).",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),%,0.1,240321,DB00788,Naproxen
>,15901348,oral uptake,"AZD3582 had intermediate and passive intestinal permeability (40 times lower than for naproxen), high systemic plasma clearance (CL), substantial gastrointestinal hydrolysis, intermediate volume of distribution (Vss; >or=3.4 L kg-1) and half-life (t1/2; 7 h), negligible plasma protein binding (approximately 0.1%), low/intermediate oral uptake (>or=13% as intact substance) and low and varying oral bioavailability (mean 1.4% in minipigs and 3.9% in dogs).",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),%,13,240322,DB00788,Naproxen
,15901348,oral bioavailability,"AZD3582 had intermediate and passive intestinal permeability (40 times lower than for naproxen), high systemic plasma clearance (CL), substantial gastrointestinal hydrolysis, intermediate volume of distribution (Vss; >or=3.4 L kg-1) and half-life (t1/2; 7 h), negligible plasma protein binding (approximately 0.1%), low/intermediate oral uptake (>or=13% as intact substance) and low and varying oral bioavailability (mean 1.4% in minipigs and 3.9% in dogs).",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),%,1.4,240323,DB00788,Naproxen
,15901348,oral bioavailability,"AZD3582 had intermediate and passive intestinal permeability (40 times lower than for naproxen), high systemic plasma clearance (CL), substantial gastrointestinal hydrolysis, intermediate volume of distribution (Vss; >or=3.4 L kg-1) and half-life (t1/2; 7 h), negligible plasma protein binding (approximately 0.1%), low/intermediate oral uptake (>or=13% as intact substance) and low and varying oral bioavailability (mean 1.4% in minipigs and 3.9% in dogs).",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),%,3.9,240324,DB00788,Naproxen
,15901348,bioavailability (F),"Despite near-complete to complete uptake of the oral dose, AZD3582 administration resulted in a lower bioavailability (F) of total naproxen than naproxen administration: 55% and 85% relative bioavailability (Frel) in rats and minipigs, respectively.",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),%,55,240325,DB00788,Naproxen
,15901348,bioavailability (F),"Despite near-complete to complete uptake of the oral dose, AZD3582 administration resulted in a lower bioavailability (F) of total naproxen than naproxen administration: 55% and 85% relative bioavailability (Frel) in rats and minipigs, respectively.",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),%,85,240326,DB00788,Naproxen
,15901348,relative bioavailability (Frel),"Despite near-complete to complete uptake of the oral dose, AZD3582 administration resulted in a lower bioavailability (F) of total naproxen than naproxen administration: 55% and 85% relative bioavailability (Frel) in rats and minipigs, respectively.",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),%,85,240327,DB00788,Naproxen
,15901348,t1/2,"Following dosing of AZD3582 or naproxen, the t1/2 of naproxen was 5, 9-10 and >40 h in rats, minipigs and dogs, respectively.",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),h,5,240328,DB00788,Naproxen
,15901348,t1/2,"Following dosing of AZD3582 or naproxen, the t1/2 of naproxen was 5, 9-10 and >40 h in rats, minipigs and dogs, respectively.",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),h,9-10,240329,DB00788,Naproxen
,15901348,t1/2,"Following dosing of AZD3582 or naproxen, the t1/2 of naproxen was 5, 9-10 and >40 h in rats, minipigs and dogs, respectively.",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),h,>,240330,DB00788,Naproxen
,15901348,t1/2,"Following dosing of AZD3582 or naproxen, the t1/2 of naproxen was 5, 9-10 and >40 h in rats, minipigs and dogs, respectively.",Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901348/),h,40,240331,DB00788,Naproxen
,9578191,Cmax,"There were no significant differences in peak plasma concentration, time to peak plasma concentration or area under the plasma concentration-time curve between bleeders or controls for any of the NSAIDs studied, apart from piroxicam Cmax being lower in bleeders at 2.07 mg l(-1) than in controls at 3.21 mg l(-1), mean difference (95% CI) -1.14 (-1.83 - -0.48), P<0.005.",Are altered pharmacokinetics of non-steroidal anti-inflammatory drugs (NSAIDs) a risk factor for gastrointestinal bleeding? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578191/),[mg] / [l],2.07,241166,DB00788,Naproxen
,9578191,Cmax,"There were no significant differences in peak plasma concentration, time to peak plasma concentration or area under the plasma concentration-time curve between bleeders or controls for any of the NSAIDs studied, apart from piroxicam Cmax being lower in bleeders at 2.07 mg l(-1) than in controls at 3.21 mg l(-1), mean difference (95% CI) -1.14 (-1.83 - -0.48), P<0.005.",Are altered pharmacokinetics of non-steroidal anti-inflammatory drugs (NSAIDs) a risk factor for gastrointestinal bleeding? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578191/),[mg] / [l],3.21,241167,DB00788,Naproxen
,3410594,Peak plasma concentrations,"Peak plasma concentrations and AUC values were 71 +/- 3.16 micrograms/ml and 685 +/- 27 micrograms/ml/h, respectively for N alone, and 72.5 +/- 2.85 micrograms/ml and 651 +/- 28 micrograms/ml/h, respectively for N + S.",Lack of influence of sulglycotide on naproxen bioavailability in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410594/),[μg] / [ml],71,246353,DB00788,Naproxen
,3410594,Peak plasma concentrations,"Peak plasma concentrations and AUC values were 71 +/- 3.16 micrograms/ml and 685 +/- 27 micrograms/ml/h, respectively for N alone, and 72.5 +/- 2.85 micrograms/ml and 651 +/- 28 micrograms/ml/h, respectively for N + S.",Lack of influence of sulglycotide on naproxen bioavailability in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410594/),[μg] / [ml],72.5,246354,DB00788,Naproxen
,3410594,AUC,"Peak plasma concentrations and AUC values were 71 +/- 3.16 micrograms/ml and 685 +/- 27 micrograms/ml/h, respectively for N alone, and 72.5 +/- 2.85 micrograms/ml and 651 +/- 28 micrograms/ml/h, respectively for N + S.",Lack of influence of sulglycotide on naproxen bioavailability in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410594/),[μg] / [h·ml],685,246355,DB00788,Naproxen
,3410594,AUC,"Peak plasma concentrations and AUC values were 71 +/- 3.16 micrograms/ml and 685 +/- 27 micrograms/ml/h, respectively for N alone, and 72.5 +/- 2.85 micrograms/ml and 651 +/- 28 micrograms/ml/h, respectively for N + S.",Lack of influence of sulglycotide on naproxen bioavailability in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410594/),[μg] / [h·ml],651,246356,DB00788,Naproxen
,3410594,t1/2 beta,"Similarly, the kinetic behavior of naproxen was not modified by the simultaneous presence of sulglycotide, as shown by the t1/2 beta-values obtained with N alone (8.39 +/- 0.31 h) and with N + S (7.93 +/- 0.30 h), and likewise by the distribution volumes at equilibrium (7.63 +/- 0.42 and 7.9 +/- 0.38, respectively), Cmax (63.3 +/- 2.86 and 60.4 +/- 2.9 micrograms/ml, respectively) and tmax (0.95 +/- 0.06 and 1.10 +/- 0.10 h, respectively).",Lack of influence of sulglycotide on naproxen bioavailability in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410594/),h,8.39,246357,DB00788,Naproxen
,3410594,t1/2 beta,"Similarly, the kinetic behavior of naproxen was not modified by the simultaneous presence of sulglycotide, as shown by the t1/2 beta-values obtained with N alone (8.39 +/- 0.31 h) and with N + S (7.93 +/- 0.30 h), and likewise by the distribution volumes at equilibrium (7.63 +/- 0.42 and 7.9 +/- 0.38, respectively), Cmax (63.3 +/- 2.86 and 60.4 +/- 2.9 micrograms/ml, respectively) and tmax (0.95 +/- 0.06 and 1.10 +/- 0.10 h, respectively).",Lack of influence of sulglycotide on naproxen bioavailability in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410594/),h,7.93,246358,DB00788,Naproxen
,3410594,distribution volumes at equilibrium,"Similarly, the kinetic behavior of naproxen was not modified by the simultaneous presence of sulglycotide, as shown by the t1/2 beta-values obtained with N alone (8.39 +/- 0.31 h) and with N + S (7.93 +/- 0.30 h), and likewise by the distribution volumes at equilibrium (7.63 +/- 0.42 and 7.9 +/- 0.38, respectively), Cmax (63.3 +/- 2.86 and 60.4 +/- 2.9 micrograms/ml, respectively) and tmax (0.95 +/- 0.06 and 1.10 +/- 0.10 h, respectively).",Lack of influence of sulglycotide on naproxen bioavailability in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410594/),,7.63,246359,DB00788,Naproxen
,3410594,distribution volumes at equilibrium,"Similarly, the kinetic behavior of naproxen was not modified by the simultaneous presence of sulglycotide, as shown by the t1/2 beta-values obtained with N alone (8.39 +/- 0.31 h) and with N + S (7.93 +/- 0.30 h), and likewise by the distribution volumes at equilibrium (7.63 +/- 0.42 and 7.9 +/- 0.38, respectively), Cmax (63.3 +/- 2.86 and 60.4 +/- 2.9 micrograms/ml, respectively) and tmax (0.95 +/- 0.06 and 1.10 +/- 0.10 h, respectively).",Lack of influence of sulglycotide on naproxen bioavailability in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410594/),,7.9,246360,DB00788,Naproxen
,3410594,Cmax,"Similarly, the kinetic behavior of naproxen was not modified by the simultaneous presence of sulglycotide, as shown by the t1/2 beta-values obtained with N alone (8.39 +/- 0.31 h) and with N + S (7.93 +/- 0.30 h), and likewise by the distribution volumes at equilibrium (7.63 +/- 0.42 and 7.9 +/- 0.38, respectively), Cmax (63.3 +/- 2.86 and 60.4 +/- 2.9 micrograms/ml, respectively) and tmax (0.95 +/- 0.06 and 1.10 +/- 0.10 h, respectively).",Lack of influence of sulglycotide on naproxen bioavailability in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410594/),[μg] / [ml],63.3,246361,DB00788,Naproxen
,3410594,Cmax,"Similarly, the kinetic behavior of naproxen was not modified by the simultaneous presence of sulglycotide, as shown by the t1/2 beta-values obtained with N alone (8.39 +/- 0.31 h) and with N + S (7.93 +/- 0.30 h), and likewise by the distribution volumes at equilibrium (7.63 +/- 0.42 and 7.9 +/- 0.38, respectively), Cmax (63.3 +/- 2.86 and 60.4 +/- 2.9 micrograms/ml, respectively) and tmax (0.95 +/- 0.06 and 1.10 +/- 0.10 h, respectively).",Lack of influence of sulglycotide on naproxen bioavailability in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410594/),[μg] / [ml],60.4,246362,DB00788,Naproxen
,3410594,tmax,"Similarly, the kinetic behavior of naproxen was not modified by the simultaneous presence of sulglycotide, as shown by the t1/2 beta-values obtained with N alone (8.39 +/- 0.31 h) and with N + S (7.93 +/- 0.30 h), and likewise by the distribution volumes at equilibrium (7.63 +/- 0.42 and 7.9 +/- 0.38, respectively), Cmax (63.3 +/- 2.86 and 60.4 +/- 2.9 micrograms/ml, respectively) and tmax (0.95 +/- 0.06 and 1.10 +/- 0.10 h, respectively).",Lack of influence of sulglycotide on naproxen bioavailability in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410594/),h,0.95,246363,DB00788,Naproxen
,3410594,tmax,"Similarly, the kinetic behavior of naproxen was not modified by the simultaneous presence of sulglycotide, as shown by the t1/2 beta-values obtained with N alone (8.39 +/- 0.31 h) and with N + S (7.93 +/- 0.30 h), and likewise by the distribution volumes at equilibrium (7.63 +/- 0.42 and 7.9 +/- 0.38, respectively), Cmax (63.3 +/- 2.86 and 60.4 +/- 2.9 micrograms/ml, respectively) and tmax (0.95 +/- 0.06 and 1.10 +/- 0.10 h, respectively).",Lack of influence of sulglycotide on naproxen bioavailability in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410594/),h,1.10,246364,DB00788,Naproxen
,10749518,apparent volume of distribution,"Celexocib is extensively protein bound, primarily to plasma albumin, and has an apparent volume of distribution of 455+/-166L in humans.",Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10749518/),l,455,252478,DB00788,Naproxen
,10749518,elimination half-life,Celecoxib is metabolised primarily by the cytochrome P450 (CYP) 2C9 isoenzyme and has an elimination half-life of about 11 hours in healthy individuals.,Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10749518/),h,11,252479,DB00788,Naproxen
,2670397,elimination half-life,"Even though diclofenac has a relatively short elimination half-life in plasma (1.5 hours), it persists in synovial fluid.",Diclofenac sodium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670397/),h,1.5,252500,DB00788,Naproxen
>,14581063,extraction efficiency,The mean extraction efficiency was >92%.,Stereospecific high-performance liquid chromatographic analysis of ibuprofen in rat serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581063/),%,92,254603,DB00788,Naproxen
,24478225,extraction recoveries,The extraction recoveries of naproxen from human plasma were between 93.0 and 98.9%.,Determination of naproxen in human plasma by GC-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24478225/),%,93.0 and 98.9,255220,DB00788,Naproxen
,24478225,LOD,"The LOD and LOQ of naproxen were 0.03 and 0.10 μg/mL, respectively.",Determination of naproxen in human plasma by GC-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24478225/),[μg] / [ml],0.03,255221,DB00788,Naproxen
,24478225,LOQ,"The LOD and LOQ of naproxen were 0.03 and 0.10 μg/mL, respectively.",Determination of naproxen in human plasma by GC-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24478225/),[μg] / [ml],0.10,255222,DB00788,Naproxen
,33948911,Vz/F,"Atogepant mean (SD) Vz/F and CL/F were 369.45 (255.68) L and 18.88 (9.28) L/h, respectively, when administered alone and 297.56 (196.01) L and 16.33 (6.11) L/h when co-administered with acetaminophen.",Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948911/),l,369.45,257041,DB00788,Naproxen
,33948911,Vz/F,"Atogepant mean (SD) Vz/F and CL/F were 369.45 (255.68) L and 18.88 (9.28) L/h, respectively, when administered alone and 297.56 (196.01) L and 16.33 (6.11) L/h when co-administered with acetaminophen.",Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948911/),l,297.56,257042,DB00788,Naproxen
,33948911,CL/F,"Atogepant mean (SD) Vz/F and CL/F were 369.45 (255.68) L and 18.88 (9.28) L/h, respectively, when administered alone and 297.56 (196.01) L and 16.33 (6.11) L/h when co-administered with acetaminophen.",Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948911/),[l] / [h],18.88,257043,DB00788,Naproxen
,33948911,CL/F,"Atogepant mean (SD) Vz/F and CL/F were 369.45 (255.68) L and 18.88 (9.28) L/h, respectively, when administered alone and 297.56 (196.01) L and 16.33 (6.11) L/h when co-administered with acetaminophen.",Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948911/),[l] / [h],16.33,257044,DB00788,Naproxen
,33948911,Vz/F,"Atogepant mean (SD) Vz/F and CL/F were 359.61 (247.99) L and 18.80 (7.78) L/h, respectively, when co-administered with naproxen.",Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948911/),l,359.61,257045,DB00788,Naproxen
,33948911,CL/F,"Atogepant mean (SD) Vz/F and CL/F were 359.61 (247.99) L and 18.80 (7.78) L/h, respectively, when co-administered with naproxen.",Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948911/),[l] / [h],18.80,257046,DB00788,Naproxen
,8533980,distribution,"The plasma disposition, after IV administration of 5 mg/kg of body weight, was described by a two-compartment model; mean +/- SD distribution and elimination half-lives were 1.42 +/- 0.42 and 8.26 +/- 2.56 hours, respectively.","Plasma and synovial fluid kinetics, disposition, and urinary excretion of naproxen in horses. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533980/),h,1.42,261810,DB00788,Naproxen
,8533980,elimination half-lives,"The plasma disposition, after IV administration of 5 mg/kg of body weight, was described by a two-compartment model; mean +/- SD distribution and elimination half-lives were 1.42 +/- 0.42 and 8.26 +/- 2.56 hours, respectively.","Plasma and synovial fluid kinetics, disposition, and urinary excretion of naproxen in horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533980/),h,8.26,261811,DB00788,Naproxen
,8533980,Plasma concentration,"Plasma concentration of naproxen after IV administration of 5 mg/kg was 55.3 +/- 13.5 and 0.61 +/- 0.42 mg/L at 5 minutes and 48 hours after its administration, respectively.","Plasma and synovial fluid kinetics, disposition, and urinary excretion of naproxen in horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533980/),[mg] / [l],55.3,261812,DB00788,Naproxen
,8533980,Plasma concentration,"Plasma concentration of naproxen after IV administration of 5 mg/kg was 55.3 +/- 13.5 and 0.61 +/- 0.42 mg/L at 5 minutes and 48 hours after its administration, respectively.","Plasma and synovial fluid kinetics, disposition, and urinary excretion of naproxen in horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533980/),[mg] / [l],0.61,261813,DB00788,Naproxen
,8533980,Steady-state volume of distribution,"Steady-state volume of distribution was 0.163 +/- 0.053 L/kg, and area under the plasma concentration time-curve was 372.1 +/- 128.2 mg/h/L.","Plasma and synovial fluid kinetics, disposition, and urinary excretion of naproxen in horses. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533980/),[l] / [kg],0.163,261814,DB00788,Naproxen
,8533980,area under the plasma concentration time-curve,"Steady-state volume of distribution was 0.163 +/- 0.053 L/kg, and area under the plasma concentration time-curve was 372.1 +/- 128.2 mg/h/L.","Plasma and synovial fluid kinetics, disposition, and urinary excretion of naproxen in horses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533980/),[mg] / [h·l],372.1,261815,DB00788,Naproxen
,8533980,peak synovial fluid concentration,"The peak synovial fluid concentration of 12.68 +/- 12.39 mg/L was measured at 6 hours, and decreased to 0.71 +/- 0.38 mg/L at 36 hours after naproxen administration.","Plasma and synovial fluid kinetics, disposition, and urinary excretion of naproxen in horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533980/),[mg] / [l],12.68,261816,DB00788,Naproxen
,8533980,peak synovial fluid concentration,"The peak synovial fluid concentration of 12.68 +/- 12.39 mg/L was measured at 6 hours, and decreased to 0.71 +/- 0.38 mg/L at 36 hours after naproxen administration.","Plasma and synovial fluid kinetics, disposition, and urinary excretion of naproxen in horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533980/),[mg] / [l],0.71,261817,DB00788,Naproxen
,8533980,appearance half-life,"The appearance half-life of naproxen in synovial fluid was 4.64 hours, and the elimination half-life was 6.73 hours.","Plasma and synovial fluid kinetics, disposition, and urinary excretion of naproxen in horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533980/),h,4.64,261818,DB00788,Naproxen
,8533980,elimination half-life,"The appearance half-life of naproxen in synovial fluid was 4.64 hours, and the elimination half-life was 6.73 hours.","Plasma and synovial fluid kinetics, disposition, and urinary excretion of naproxen in horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533980/),h,6.73,261819,DB00788,Naproxen
,8533980,Total body clearance,Total body clearance was 0.015 +/- 0.006 L/h/kg.,"Plasma and synovial fluid kinetics, disposition, and urinary excretion of naproxen in horses. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533980/),[l] / [h·kg],0.015,261820,DB00788,Naproxen
,8533980,percentage of plasma protein binding,The percentage of plasma protein binding was 97.0 +/- 2.9% at plasma concentrations between 5 and 100 mg/L.,"Plasma and synovial fluid kinetics, disposition, and urinary excretion of naproxen in horses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533980/),%,97.0,261821,DB00788,Naproxen
,18397691,Maximal inhibition,"Maximal inhibition after a single dose and at steady state were as follows: 94% and 93% (COX-1), and 79% and 85% (COX-2).",Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397691/),%,94,265467,DB00788,Naproxen
,18397691,Maximal inhibition,"Maximal inhibition after a single dose and at steady state were as follows: 94% and 93% (COX-1), and 79% and 85% (COX-2).",Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397691/),%,93,265468,DB00788,Naproxen
,18397691,Maximal inhibition,"Maximal inhibition after a single dose and at steady state were as follows: 94% and 93% (COX-1), and 79% and 85% (COX-2).",Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397691/),%,79,265469,DB00788,Naproxen
,18397691,Maximal inhibition,"Maximal inhibition after a single dose and at steady state were as follows: 94% and 93% (COX-1), and 79% and 85% (COX-2).",Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397691/),%,85,265470,DB00788,Naproxen
,18397691,IC50,"For both isoenzymes, COX inhibition correlated with naproxen plasma levels (ex vivo IC50 values of 35.48 micromol/l (COX-1) and 64.62 micromol/l (COX-2)).",Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397691/),[μM] / [l],35.48,265471,DB00788,Naproxen
,18397691,IC50,"For both isoenzymes, COX inhibition correlated with naproxen plasma levels (ex vivo IC50 values of 35.48 micromol/l (COX-1) and 64.62 micromol/l (COX-2)).",Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397691/),[μM] / [l],64.62,265472,DB00788,Naproxen
,21347567,IC(50),"The IC(50) values (95% CI) of naproxen for analgesia (27 (0-130) μM), antipyretics (40 (30-65) μM) and inhibition of PGE(2) (13 (6-45) μM) were in similar range, whereas inhibition of TXB(2) (5 (4-8) μM) was observed at lower concentrations.","Pharmacokinetic-pharmacodynamic modeling of the inhibitory effects of naproxen on the time-courses of inflammatory pain, fever, and the ex vivo synthesis of TXB2 and PGE2 in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21347567/),μM,27,266033,DB00788,Naproxen
,21347567,IC(50),"The IC(50) values (95% CI) of naproxen for analgesia (27 (0-130) μM), antipyretics (40 (30-65) μM) and inhibition of PGE(2) (13 (6-45) μM) were in similar range, whereas inhibition of TXB(2) (5 (4-8) μM) was observed at lower concentrations.","Pharmacokinetic-pharmacodynamic modeling of the inhibitory effects of naproxen on the time-courses of inflammatory pain, fever, and the ex vivo synthesis of TXB2 and PGE2 in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21347567/),μM,40,266034,DB00788,Naproxen
,21347567,IC(50),"The IC(50) values (95% CI) of naproxen for analgesia (27 (0-130) μM), antipyretics (40 (30-65) μM) and inhibition of PGE(2) (13 (6-45) μM) were in similar range, whereas inhibition of TXB(2) (5 (4-8) μM) was observed at lower concentrations.","Pharmacokinetic-pharmacodynamic modeling of the inhibitory effects of naproxen on the time-courses of inflammatory pain, fever, and the ex vivo synthesis of TXB2 and PGE2 in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21347567/),μM,13,266035,DB00788,Naproxen
,21347567,IC(50),"The IC(50) values (95% CI) of naproxen for analgesia (27 (0-130) μM), antipyretics (40 (30-65) μM) and inhibition of PGE(2) (13 (6-45) μM) were in similar range, whereas inhibition of TXB(2) (5 (4-8) μM) was observed at lower concentrations.","Pharmacokinetic-pharmacodynamic modeling of the inhibitory effects of naproxen on the time-courses of inflammatory pain, fever, and the ex vivo synthesis of TXB2 and PGE2 in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21347567/),μM,5,266036,DB00788,Naproxen
,7439246,elimination half-life,In healthy subjects the elimination half-life of naproxen was 17.7 +/- 3.0 h (mean +/- SD) and it was not significantly prolonged in patients with renal failure (18.1 +/- 5.3) h.,Pharmacokinetics of naproxen in subjects with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439246/),h,17.7,266861,DB00788,Naproxen
,7439246,elimination half-life,In healthy subjects the elimination half-life of naproxen was 17.7 +/- 3.0 h (mean +/- SD) and it was not significantly prolonged in patients with renal failure (18.1 +/- 5.3) h.,Pharmacokinetics of naproxen in subjects with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439246/),h,18.1,266862,DB00788,Naproxen
,7439246,apparent half-life,"The apparent half-life of desmethylnaproxen was of the same order of magnitude as that of naproxen (18.6 +/- 4.4 h), and was also independent of renal function.",Pharmacokinetics of naproxen in subjects with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439246/),h,18.6,266863,DB00788,Naproxen
,24388762,maximum concentration (Cmax,"After the first administration, the maximum concentration (Cmax 44.21 ± 9.21 μg/mL) was reached at 2.5 ± 0.58 h post-treatment, the harmonic mean terminal half-life was 6.96 ± 1.73 h, AUC0-24h was 459.71 ± 69.95 h μg/mL, MRT was 7.44 ± 0.74 h and protein binding was 98.47 ± 2.72%.",Naproxen in the horse: pharmacokinetics and side effects in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24388762/),[μg] / [ml],44.21,267608,DB00788,Naproxen
,24388762,terminal half-life,"After the first administration, the maximum concentration (Cmax 44.21 ± 9.21 μg/mL) was reached at 2.5 ± 0.58 h post-treatment, the harmonic mean terminal half-life was 6.96 ± 1.73 h, AUC0-24h was 459.71 ± 69.95 h μg/mL, MRT was 7.44 ± 0.74 h and protein binding was 98.47 ± 2.72%.",Naproxen in the horse: pharmacokinetics and side effects in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24388762/),h,6.96,267609,DB00788,Naproxen
,24388762,AUC0-24h,"After the first administration, the maximum concentration (Cmax 44.21 ± 9.21 μg/mL) was reached at 2.5 ± 0.58 h post-treatment, the harmonic mean terminal half-life was 6.96 ± 1.73 h, AUC0-24h was 459.71 ± 69.95 h μg/mL, MRT was 7.44 ± 0.74 h and protein binding was 98.47 ± 2.72%.",Naproxen in the horse: pharmacokinetics and side effects in the elderly. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24388762/),[h·μg] / [ml],459.71,267610,DB00788,Naproxen
,24388762,MRT,"After the first administration, the maximum concentration (Cmax 44.21 ± 9.21 μg/mL) was reached at 2.5 ± 0.58 h post-treatment, the harmonic mean terminal half-life was 6.96 ± 1.73 h, AUC0-24h was 459.71 ± 69.95 h μg/mL, MRT was 7.44 ± 0.74 h and protein binding was 98.47 ± 2.72%.",Naproxen in the horse: pharmacokinetics and side effects in the elderly. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24388762/),h,7.44,267611,DB00788,Naproxen
,24388762,protein binding,"After the first administration, the maximum concentration (Cmax 44.21 ± 9.21 μg/mL) was reached at 2.5 ± 0.58 h post-treatment, the harmonic mean terminal half-life was 6.96 ± 1.73 h, AUC0-24h was 459.71 ± 69.95 h μg/mL, MRT was 7.44 ± 0.74 h and protein binding was 98.47 ± 2.72%.",Naproxen in the horse: pharmacokinetics and side effects in the elderly. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24388762/),%,98.47,267612,DB00788,Naproxen
,26083965,permeability coefficient,"Naringenin was absorbed well throughout the gastrointestinal tract but mainly in the small intestine and colon (mean permeability coefficient 7.80 (SD 1.54) × 10(-4) cm/s and 5.49 (SD 1.86) × 10(-4) cm/s, respectively), at a level similar to the highly permeable compound, naproxen (6.39 (SD 1.23) × 10(-4) cm/s).",High gastrointestinal permeability and local metabolism of naringenin: influence of antibiotic treatment on absorption and metabolism. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26083965/),[cm] / [s],7.80,268276,DB00788,Naproxen
,26083965,permeability coefficient,"Naringenin was absorbed well throughout the gastrointestinal tract but mainly in the small intestine and colon (mean permeability coefficient 7.80 (SD 1.54) × 10(-4) cm/s and 5.49 (SD 1.86) × 10(-4) cm/s, respectively), at a level similar to the highly permeable compound, naproxen (6.39 (SD 1.23) × 10(-4) cm/s).",High gastrointestinal permeability and local metabolism of naringenin: influence of antibiotic treatment on absorption and metabolism. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26083965/),[cm] / [s],5.49,268277,DB00788,Naproxen
,26083965,permeability coefficient,"Naringenin was absorbed well throughout the gastrointestinal tract but mainly in the small intestine and colon (mean permeability coefficient 7.80 (SD 1.54) × 10(-4) cm/s and 5.49 (SD 1.86) × 10(-4) cm/s, respectively), at a level similar to the highly permeable compound, naproxen (6.39 (SD 1.23) × 10(-4) cm/s).",High gastrointestinal permeability and local metabolism of naringenin: influence of antibiotic treatment on absorption and metabolism. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26083965/),[cm] / [s],6.39,268278,DB00788,Naproxen
,8964239,elimination half life,Naproxen concentrations (elimination half life of about 72 h in dogs) achieved equilibrium between tissue fluid and plasma concentration.,[The tissue cage in dogs--a pharmacologic model for the representation of plasma and tissue kinetics]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8964239/),h,72,273622,DB00788,Naproxen
